Note : Les descriptions sont présentées dans la langue officielle dans laquelle elles ont été soumises.
CA 02341142 2001-03-O1
WO 00/12758 PCT/US99/19655
w
A NOVEh METHOD OF DIAGNOSING,
MONITORING, STAGING, IMAGING AND TREATING VARIOUS CANCERS
FIEhD OF THE INVENTION
This invention relates, in part, to newly developed
assays for detecting, diagnosing, monitoring, staging,
prognosticating, imaging and treating various cancers,
particularly gynecologic cancer including ovarian, uterine
endometrial and breast cancer, and lung cancer.
BACKGROUND OF THE INVENTION
IO The American Cancer Society has estimated that over
560,000 Americans will die this year from cancer. Cancer is
the second leading cause of death in the United States,
exceeded only by heart disease. It has been estimated that
over one million new cancer cases will be diagnosed in 1999
alone.
In women, gynecologic cancers account for more than one-
fourth of the malignancies.
Of the gynecologic cancers, breast cancer is the most
common. According to the Women's Cancer Network, 1 out of
every 8 women in the United States is as risk of developing
breast cancer, and 1 out of every 28 women are at risk of
dying from breast cancer. Approximately 770 of women
diagnosed with breast cancer are over the age of 50.
However, breast cancer is the leading cause of death in women
between the ages of 40 and 55.
Carcinoma of the ovary is another very common
gynecologic cancer. Approximately one in 70 women will
develop ovarian cancer during her lifetime. An estimated
14,500 deaths in 1995 resulted from ovarian cancer. It causes
more deaths than any other cancer of the female reproductive
system. Ovarian cancer often does not cause any noticeable
CA 02341142 2001-03-O1
WO 00/12758 PCTNS99/19655
- 2 -
symptoms. Some possible warning signals, however, are an
enlarged abdomen due to an accumulation of fluid or vague
digestive disturbances (discomfort, gas or distention) in
women over 40; rarely there will be abnormal vaginal bleeding.
Periodic, complete pelvic examinations are important; a Pap
test does not detect ovarian cancer. Annual pelvic exams are
recommended for women over 40.
Also common in women is endometrial cancer or carcinoma
of the lining of the uterus. According to the Women's Cancer
Center endometrial cancer accounts for approximately 13% of
all malignancies in women. There are about 34,000 cases of
endometrial cancer diagnosed in the United States each year.
Uterine sarcoma is another type of uterine malignancy
much more rare as compared to other gynecologic cancers. In
uterine sarcoma, malignant cells start growing in the muscles
or other supporting tissues of the uterus. Sarcoma of the
uterus is different from cancer of the endometrium, a disease
in which cancer cells start growing in the lining of the
uterus. This uterine cancer usually begins after menopause.
Women who have received therapy with high-dose X-rays
(external beam radiation therapy) to their pelvis are at a
higher risk to develop sarcoma of the uterus. These X-rays
are sometimes given to women to stop bleeding from the uterus.
Lung cancer is the second most prevalent type of cancer
for both men and women in the United States and is the most
common cause of cancer death in both sexes. Lung cancer can
result from a primary tumor originating in the lung or a
secondary tumor which has spread from another organ such as
the bowel or breast. Primary lung cancer is divided into
three main types; small cell lung cancer; non-small cell lung
cancer; and mesothelioma. Small cell lung cancer is also
called "Oat Cell" lung cancer because the cancer cells are a
distinctive oat shape. There are three types of non-small cell
lung cancer. These are grouped together because they behave
in a similar way and respond to treatment differently to small
CA 02341142 2001-03-O1
WO 00/12758 PCT/US99/19655
- 3 -
cell lung cancer. The three types are squamous cell
carcinoma, adenocarcinoma, and large cell carcinoma. Squamous
cell cancer is the most common type of lung cancer. It
develops from the cells that line the airways. Adenocarcinoma
also develops from the cells that line the airways. However,
adenocarcinoma develops from a particular type of cell that
produces mucus (phlegm). Large cell lung cancer has been thus
named because the cells look large and rounded when they are
viewed under a microscope. Mesothelioma is a rare type of
cancer which affects the covering of the lung called the
pleura. Mesothelioma is often caused by exposure to asbestos.
Procedures used for detecting, diagnosing, monitoring,
staging, and prognosticating each of these types of cancer are
of critical importance to the outcome of the patient. In all
25 cases, patients diagnosed early in development of the cancer
generally have a much greater five-year survival rate as
compared to the survival rate for patients diagnosed with a
cancer which has metastasized. New diagnostic methods which
are more sensitive and specific for early detection of various
types of cancer are clearly needed.
In the present invention methods are provided for
detecting, diagnosing, monitoring, staging, prognosticating,
in vivo imaging and treating selected cancers including, but
not limited to, gynecologic cancers such as ovarian, breast
endometrial and/or uterine cancer, and lung cancer via
detection of a Cancer Specific Genes (CSGs). Nine CGSs have
been identified and refer, among other things, to native
proteins expressed by the genes comprising the polynucleotide
sequences of any of SEQ ID NO: 1, 2, 3, ~, 5, 6, 7, 8 or 9.
In the alternative, what is meant by the nine CSGs as used
herein, means the native mRNAs encoded by the genes comprising
any of the polynucleotide sequences of SEQ ID NO: l, 2, 3, 4,
5, 6, 7, 8 or 9 or it can refer to the actual genes comprising
any of the polynucleotide sequences of SEQ ID NO: 1, 2, 3, 4,
CA 02341142 2001-03-O1
WO 00/12758 PCT/US99/19655
_ q _
5, 6, 7, $ or 9. Fragments of the CSGs such as those depicted
in SEQ ID NO:10, 11, 12, 13 or 14 can also be detected.
Other objects, features, advantages and aspects of the
present invention will become apparent to those of skill in
the art from the following description. It should be
understood, however, that the following description and the
specific examples, while indicating preferred embodiments of
the invention are given by way of illustration only. Various
changes and modifications within the spirit and scope of the
disclosed invention will become readily apparent to those
skilled in the art from reading the following description and
from reading the other parts of the present disclosure.
SU7N~1ARY OF THE INVENTION
Toward these ends, and others, it is an object of the
present invention to provide a method for diagnosing the
presence of selected cancers by analyzing for changes in
levels of CSG in cells, tissues or bodily fluids compared with
levels of CSG in preferably the same cells, tissues, or bodily
fluid type of a normal human control, wherein a change in
levels of CSG in the patient versus the normal human control
is associated with the selected cancer. For the purposes of
this invention, by "selected cancer" it is meant to include
gynecologic cancers such as ovarian, breast, endometrial and
uterine cancer, and lung cancer.
Further provided is a method of diagnosing metastatic
cancer in a patient having a selected cancer which is not
known to have metastasized by identifying a human patient
suspected of having a selected cancer that has metastasized;
analyzing a sample of cells, tissues, or bodily fluid from
such patient for CSG; comparing the CSG levels in such cells,
tissues, or bodily fluid with levels of CSG in preferably the
same cells, tissues, or bodily fluid type of a normal human
control, wherein an increase in CSG levels in the patient
CA 02341142 2001-03-O1
WO 00/12758 PCT/US99/19655
- 5 -
versus the normal human control is associated with a cancer
which has metastasized.
Also provided by the invention is a method of staging
selected cancers in a human patient by identifying a human
patient having such cancer; analyzing a sample of cells,
tissues, or bodily fluid from such patient for CSG; comparing
CSG levels in such cells, tissues, or bodily fluid with levels
of CSG in preferably the same cells; tissues, or bodily fluid
type of a normal human control sample, wherein an increase in
CSG levels in the patient versus the normal human control is
associated with a cancer which is progressing and a decrease
in the levels of CSG is associated with a cancer which is
regressing or in remission.
Further provided is a method of monitoring selected
cancers in patients for the onset of metastasis. The method
comprises identifying a human patient having a selected cancer
that is not known to have metastasized; periodically analyzing
a sample of cells, tissues, or bodily fluid from such patient
for CSG; comparing the CSG levels in such cells, tissues, or
bodily fluid with levels of CSG in preferably the same cells,
tissues, or bodily fluid type of a normal human control
sample, wherein an increase in CSG levels in the patient
versus the normal human control is associated with a cancer
which has metastasized.
Further provided is a method of monitoring the change
in stage of selected cancers in humans having such cancer by
looking at levels of CSG. The method comprises identifying
a human patient having a selected cancer; periodically
analyzing a sample of cells, tissues, or bodily fluid from
such patient for CSG; comparing the CSG levels in such cells,
tissue, or bodily fluid with levels of CSG in preferably the
same cells, tissues, or bodily fluid type of a normal human
control sample, wherein an increase in CSG levels in the
patient versus the normal human control is associated with a
cancer which is progressing and a decrease in the levels of
CA 02341142 2001-03-O1
WO 00/12758 PCT/US99/19655
- 6 -
CSG is associated with a cancer which is regressing or in
remission.
Further provided are antibodies against CSG or fragments
of such antibodies which can be used to detect or image
localization of CSG in a patient for the purpose of detecting
or diagnosing selected cancers. Such antibodies can be
polyclonal or monoclonal, or prepared by molecular biology
techniques. The term "antibody", as used herein and
throughout the instant specification is also meant to include
aptamers and single-stranded oligonucleotides such as those
derived from an in vitro evolution protocol referred to as
SELEX and well known to those skilled in the art. Antibodies
can be labeled with a variety of detectable labels including,
but not limited to, radioisotopes and paramagnetic metals.
These antibodies or fragments thereof can also be used as
therapeutic agents in the treatment of diseases characterized
by expression of a CSG. In therapeutic applications, the
antibody can be used without or with derivatization to a
cytotoxic agent such as a radioisotope, enzyme, toxin, drug
or a prodrug.
Other objects, features, advantages and aspects of the
present invention will become apparent to those of skill in
the art from the following description. It should be
understood, however, that the following description and the
specific examples, while indicating preferred embodiments of
the invention, are given by way of illustration only. Various
changes and modifications within the spirit and scope of the
disclosed invention will become readily apparent to those
skilled in the art from reading the following description and
from reading the other parts of the present disclosure.
DETAILED DESCRIPTION OF THE INVENTION
The present invention relates to diagnostic assays and
methods, both quantitative and qualitative for detecting,
diagnosing, monitoring, staging and prognosticating selected
CA 02341142 2001-03-O1
WO 00/12758 PCT/US99/19655
_ 7 _
cancers by comparing levels of CSG with those of CSG in a
normal human control. What is meant by levels of CSG as used
herein is levels of the native protein expressed by the gene
comprising the polynucleotide sequence of any of SEQ ID NO:
2, 2, 3, 4, 5, 6, 7, 8 or 9. In the alternative, what is
meant by levels of CSG as used herein is levels of the native
mRNA encoded by the gene comprising any of the polynucleotide
sequence of SEQ ID N0: 1, 2, 3, 4, 5, 6, 7, 8 or 9 or levels
of the gene comprising any of the polynucleotide sequences of
SEQ ID N0:1, 2, 3, 4, 5, 6, 7, 8 or 9. Fragments of CSGs such
as those depicted in SEQ ID N0: 10, 11, 12, 13 and 14 can also
be detected. Such levels are preferably measured in at least
one of cells, tissues and/or bodily fluids, including
determination of normal and abnormal levels. Thus, for
instance, a diagnostic assay in accordance with the invention
for diagnosing over-expression of CSG protein compared to
normal control bodily fluids, cells, or tissue samples may be
used to diagnose the presence of selected cancers. What is
meant by "selected cancers" as used herein is a gynecologic
cancer such as ovarian, breast, endometrial or uterine cancer,
or lung case.
Any of the 9 CSGs can be measured alone in the methods
of the invention, or all together or any combination thereof.
However, for methods relating to gynecologic cancers including
ovarian, breast, endometrial and uterine cancer, it is
preferred that levels of CSG comprising SEQ ID NO:1 or a
fragment thereof be determined. Exemplary fragments of this
CSG which can be detected are depicted in SEQ ID NO: 10, 11,
12, and 13. For methods relating to lung cancer and
gynecologic cancers including ovarian, endometrial and
uterine, it is preferred that levels of CSG comprising SEQ ID
N0:2 or 9 be determined. Fragments of this CSG such as that
depicted in SEQ ID N0:14 can also be detected. For methods
relating to ovarian cancer, determination of levels of CSG
comprising SEQ ID N0:3 is also preferred.
CA 02341142 2001-03-O1
WO 00/12758 PCT/US99/19655
_ g _
All the methods of the present invention may optionally
include measuring the levels of other cancer markers as well
as CSG. Other cancer markers, in addition to CSG, useful in
the present invention will depend on the cancer being tested
and are known to those of skill in the art.
Diagnostic Assays
The present invention provides methods for diagnosing
the presence of selected cancers by analyzing for changes in
levels of CSG in cells, tissues or bodily fluids compared with
levels of CSG in cells, tissues or bodily fluids of preferably
the same type from a normal human control, wherein a change
in levels of CSG in the patient versus the normal human
control is associated with the presence of a selected cancer.
Without limiting the instant invention, typically, for
a quantitative diagnostic assay a positive result indicating
the patient being tested has cancer is one in which cells,
tissues or bodily fluid levels of the cancer marker, such as
CSG, are at least two times higher, and most preferably are
at least five times higher, than in preferably the same cells,
tissues or bodily fluid of a normal human control.
The present invention also provides a method of
diagnosing metastases of selected cancers in a patient having
a selected cancer which has not yet metastasized for the onset
of metastasis. In the method of the present invention, a
human cancer patient suspected of having a selected cancer
which may have metastasized (but which was not previously
known to have metastasized) is identified. This is
accomplished by a variety of means known to those of skill in
the art. For example, in the case of ovarian cancer, patients
are typically diagnosed with ovarian cancer following surgical
staging and monitoring of CA125 levels. Traditional
detection methods are also available and well known for other
selected cancers which can be diagnosed by determination of
CSG levels in a patient.
CA 02341142 2001-03-O1
WO 00/12758 PCT/US99/19655
- 9 -
In the present invention, determining the presence of
CSG levels in cells, tissues or bodily fluid, is particularly
useful for discriminating between a selected cancer which has
not metastasized and a selected cancer which has metastasized.
Existing techniques have difficulty discriminating between
cancers which have metastasized and cancers which have not
metastasized and proper treatment selection is often dependent
upon such knowledge.
In the present invention, the cancer marker levels
measured in such cells, tissues or bodily fluid is CSG, and
are compared with levels of CSG in preferably the same cells,
tissue or bodily fluid type of a normal human control. That
is, if the cancer marker being observed is CSG in serum, this
level is preferably compared with the level of CSG in serum
of a normal human patient. An increase in the CSG in the
patient versus the normal human control is associated with
a cancer which has metastasized.
Without limiting the instant invention, typically, for
a quantitative diagnostic assay a positive result indicating
the cancer in the patient being tested or monitored has
metastasized is one in which cells, tissues or bodily fluid
levels of the cancer marker, such as CSG, are at least two
times higher, and most preferably are at least five times
higher, than in preferably the same cells, tissues or bodily
fluid of a normal patient. .
Normal human control as used herein includes a human
patient without cancer and/or non cancerous samples from the
patient; in the methods for diagnosing or monitoring for
metastasis, normal human control may also include samples from
a human patient that is determined by rel=fable methods to have
a selected cancer which has not metastasized.
Staging
The invention also provides a method of staging selected
cancers in human patients. The method comprises identifying
a human patient having a selected cancer and analyzing a
CA 02341142 2001-03-O1
WO 00/12758 PCT/US99/19655
- 10 -
sample of cells, tissues or bodily fluid from such human
patient for CSG. Then, the method compares CSG levels in such
cells, tissues or bodily fluid with levels of CSG in
preferably the same cells, tissues or bodily fluid type of a
normal human control sample, wherein an increase in CSG levels
in the human patient versus the normal human control is
associated with a cancer which is progressing and a decrease
in the levels of CSG is associated with a cancer which is
regressing or in remission.,
Monitoring
Further provided is a method of monitoring selected
cancers in humans for the onset of metastasis. The method
comprises identifying a human patient having a selected cancer
that is not known to have metastasized; periodically analyzing
a sample of cells, tissues or bodily fluid from such human
patient for CSG; comparing the CSG levels in such cells,
tissues or bodily fluid with levels of CSG in preferably the
same cells, tissues or bodily fluid type of a normal human
control sample, wherein an increase in CSG levels in the human
patient versus the normal human control is associated with a
cancer which has metastasized.
Further provided by this invention is a method of
monitoring the change in stage of selected cancers in humans
having such cancers. The method comprises identifying a human
patient having a selected cancer; periodically analyzing a
sample of cells, tissues or bodily fluid from such human
patient for CSG; comparing the CSG levels in such cells,
tissues or bodily fluid with levels of CSG in preferably the
same cells, tissues or bodily fluid type of a normal human
control sample, wherein an increase in CSG levels in the human
patient versus the normal human control is associated with a
cancer which is progressing in stage and a decrease in the
levels of CSG is associated with a cancer which is regressing
in stage or in remission.
CA 02341142 2001-03-O1
WO 00/12758 PCT/US99/19655
- 11 -
Monitoring such patient for onset of metastasis is
periodic and preferably done on a quarterly basis. However,
this may be more or less frequent depending on the cancer, the
particular patient, and the stage of the cancer.
Assay Techniques
Assay techniques that can be used to determine levels
of gene expression, such as CSG of the present invention, in
a sample derived from a patient are well known to those of
skill in the art. Such assay methods include
radioimmunoassays, reverse transcriptase PCR (RT-PCR) assays,
immunohistochemistry assays, in situ hybridization assays,
ccmpetitive-binding assays, Western Blot analyses, ELISA
assays and proteomic approaches. Among these, ELISAs are
frequently preferred to diagnose a gene's expressed protein
in biological fluids.
An ELISA assay initially comprises preparing an
antibody, if not readily available from a commercial source,
specific to CSG, preferably a monoclonal antibody. In
addition a reporter antibody generally is prepared which binds
specifically to CSG. The reporter antibody is attached to a
detectable reagent such as radioactive, fluorescent or
enzymatic reagent, for example horseradish peroxidase enzyme
or alkaline phosphatase.
To carry out the ELISA, antibody specific to CSG is
incubated on a solid support, e.g. a polystyrene dish, that
binds the antibody. Any free protein binding sites on the
dish are then covered by incubating with a non-specific
protein such as bovine serum albumin. Next, the sample to be
analyzed is incubated in the dish, during which time CSG binds
to the specific antibody attached to the polystyrene dish.
Unbound sample is washed out with buffer. A reporter antibody
specifically directed to CSG and linked to horseradish
peroxidase is placed in the dish resulting in binding of the
reporter antibody to any monoclonal antibody bound to CSG.
Unattached reporter antibody is then washed out. Reagents for
CA 02341142 2001-03-O1
WO 00/12758 PCT/US99/19655
- I2 -
peroxidase activity, including a colorimetric substrate are
then added to the dish. Immobilized peroxidase, linked to CSG
antibodies, produces a colored reaction product. The amount
of color developed in a given time period is proportional to
the amount of CSG protein present in the sample. Quantitative
results typically are obtained by reference to a standard
curve.
A competition assay may be employed wherein antibodies
specific to CSG attached to.a solid support and labeled CSG
and a sample derived from the host are passed over the solid
support and the amount of label detected attached to the solid
support can be correlated to a quantity of CSG in the sample.
Nucleic acid methods may be used to detect CSG mRNA as
a marker for selected cancers. Polymerase chain reaction
(PCR) and other nucleic acid methods, such as ligase chain
reaction (LCR) and nucleic acid sequence based amplification
(NASABA), can be used to detect malignant cells for diagnosis
and monitoring of the various selected malignancies. For
example, reverse-transcriptase PCR (RT-PCR} is a powerful
technique which can be used to detect the presence of a
specific mRNA population in a complex mixture of thousands of
other mRNA species. In RT-PCR, an mRNA species is first
reverse transcribed to complementary DNA (cDNA) with use of
the enzyme reverse transcriptase; the cDNA is then amplified
as in a standard PCR reaction. RT-PCR can thus reveal by
amplification the presence of a single species of mRNA.
Accordingly, if the mRNA is highly specific for the cell that
produces it, RT-PCR can be used to identify the presence of
a specific type of cell.
Hybridization to clones or oligonur_leotides arrayed on
a solid support (i.e. gridding) can be used to both detect the
expression of and quantitate the level of expression of that
gene. In this approach, a cDNA encoding the CSG gene is
fixed to a substrate. The substrate may be of any suitable
type including but not limited to glass, nitrocellulose, nylon
CA 02341142 2001-03-O1
WO 00/12758 PCT/US99/19655
- 13 -
or plastic. At least a portion of the DNA encoding the CSG
gene is attached to the substrate and then incubated with the
analyte, which may be RNA or a complementary DNA (cDNA) copy
of the RNA, isolated from the tissue of interest.
Hybridization between the substrate bound DNA and the analyte
can be detected and quantitated by several means including but
not limited to radioactive labeling or fluorescence labeling
of the analyte or a secondary molecule designed to detect the
hybrid. Quantitation of th.e level of gene expression can be
done by comparison of the intensity of the signal from the
analyte compared with that determined from known standards.
The standards can be obtained by in vitro transcription of the
target gene, quantitating the yield, and then using that
material to generate a standard curve.
Of the proteomic approaches, 2D electrophoresis is a
technique well known to those in the art. Isolation of
individual proteins from a sample such as serum is
accomplished using sequential separation of proteins by
different characteristics usually on polyacrylamide gels.
First, proteins are separated by size using an electric
current. The current acts uniformly on all proteins, so
smaller proteins move farther on the gel than larger proteins.
The second dimension applies a current perpendicular to the
first and separates proteins not on the basis of size but on
the specific electric charge carried by. each protein. Since
no two proteins with different sequences are identical on the
basis of both size and charge, the result of a 2D separation
is a square gel in which each protein occupies a unique spot.
Analysis of the spots with chemical or antibody probes, or
subsequent protein microsequencing can reveal the relative
abundance of a given protein and the identity of the proteins
in the sample.
The above tests can be carried out on samples derived
from a variety of patients' cells, bodily fluids and/or tissue
extracts (homogenates or solubilized tissue) such as from
CA 02341142 2001-03-O1
WO 00/12758 PCT/US99/19655
- 14 -
tissue biopsy and autopsy material. Bodily fluids useful in
the present invention include blood, urine, saliva or any
other bodily secretion or derivative thereof. Blood can
include whole blood, plasma, serum or any derivative of blood.
In Vivo Antibody Use
Antibodies against CSG can also be used in vivo in
patients suspected of suffering from a selected cancer
including lung cancer or gynecologic cancers such as ovarian,
breast, endometrial or uterine cancer. Specifically,
antibodies against a CSG can be injected into a patient
suspected of having a selected cancer for diagnostic and/or
therapeutic purposes. The use of antibodies for in vivo
diagnosis is well known in the art. For example, antibody-
chelators labeled with Indium-111 have been described for use
in the radioimmunoscintographic imaging of carcinoembryonic
antigen expressing tumors (Sumerdon et al. Nucl. Med. Biol.
1990 17:247-254). In particular, these antibody-chelators
have been used in detecting tumors in patients suspected of
having recurrent colorectal cancer (Griffin et al. 3. Clin.
Onc. 1991 9:631-540). Antibodies with paramagnetic ions as
labels for use in magnetic resonance imaging have also been
described (Lauffer, R.B. Magnetic Resonance in Medicine 1991
22:339-342). Antibodies directed against CSGs can be used in
a similar manner. Labeled antibodies against a CSG can be
injected into patients suspected of having a selected cancer
for the purpose of diagnosing or staging of the disease status
of the patient. The label used will be selected in accordance
with the imaging modality to be used. For example,
radioactive labels such as Indium-111, Technetium-99m or
Iodine-131 can be used for planar scans or single photon
emission computed tomography (SPECT). Positron emitting
labels such as Fluorine-19 can be used in positron emission
tomography. Paramagnetic ions such as Gadlinium (III) or
Manganese (II) can used in magnetic resonance imaging (MRI).
Localization of the label permits determination of the spread
CA 02341142 2001-03-O1
WO 00/12758 PCT/US99/19655
- 15 -
of the cancer. The amount of label within an organ or tissue
also allows determination of the presence or absence of cancer
in that organ or tissue.
For patients diagnosed with a selected cancer, injection
of an antibody against a CSG can also have a therapeutic
benefit. The antibody may exert its therapeutic effect alone.
Alternatively, the antibody is conjugated to a cytotoxic agent
such as a drug, toxin or radionuclide to enhance its
therapeutic effect. Drug .monoclonal antibodies have been
described in the art for example by Gannett and Baldwin,
Cancer Research 1986 46:2407-2412. The use of toxins
conjugated to monoclonal antibodies for the therapy of various
cancers has also been described by Pastan et al. Cell 1986
47:641-648. Yttrium-90 labeled monoclonal antibodies have
been described for maximization of dose delivered to the tumor
while limiting toxicity to normal tissues (Goodwin and Meares
Cancer Supplement 1997 80:2675-2680). Other cytotoxic
radionuclides including, but not limited to Copper-67, Iodine
131 and Rhenium-186 can also be used for labeling of
antibodies against CSGs.
Antibodies which can be used in these in vivo methods
include both polyclonal and monoclonal antibodies and
antibodies prepared via molecular biology techniques.
Antibody fragments and aptamers and single-stranded
oligonucleotides such as those derived from an in vitro
evolution protocol referred to as SELEX and well known to
those skilled in the art can also be used.
The present invention is further described by the
following examples. These examples are provided solely to
illustrate the invention by reference to specific embodiments.
The exemplifications, while illustrating certain aspects of
the invention, do not portray the limitations or circumscribe
the scope of the disclosed invention.
CA 02341142 2001-03-O1
WO 00/12758 PCT/US99/19655
- 16 -
EXAMPLES
Example 1:
Identification of CSGs were carried out by a systematic
analysis of data in the LIFESEQ database available from Incyte
Pharmaceuticals, Palo Alto, CA, using the data mining Cancer
Leads Automatic Search Package (CLASP) developed by diaDexus
LLC, Santa Clara, CA.
The CLASP performs the following steps: selection of
highly expressed organ specific genes based on the abundance
level of the corresponding EST in the targeted organ versus
all the other organs; analysis of the expression level of each
highly expressed organ specific genes in normal, tumor tissue,
disease tissue and tissue libraries associated with tumor or
disease. Selection of the candidates demonstrating component
ESTs were exclusively or more frequently found in tumor
libraries. The CLASP allows the identification of highly
expressed organ and cancer specific genes. A final manual in
depth evaluation is then performed to finalize the CSGs
selection.
Table l: CSG Sequences
SEQ ID NO: Clone ID Gene ID
1 16656592 234617
2 1283171 332459
3 1649377 48-1154
4 236044H1 none assigned
5 none assigned 255687
6 none assigned 251313
7 none assigned 12029
8 none assigned 251804
The following examples are carried out using standard
techniques, which are well known and routine to those of skill
in the art, except where otherwise described in detail.
CA 02341142 2001-03-O1
WO 00/12758 PCT/US99/19655
- 17 -
Routine molecular biology techniques of the following example
can be carried out as described in standard laboratory
manuals, such as Sambrook et~ al., MOLECULAR CLONING: A
LABORATORY MANUAL, 2nd Ed.; Cold Spring Harbor Laboratory
Press, Cold Spring Harbor, N.Y. (1989).
Example 2: Relative Quantitation of Gene Expression
Real-Time quantitative PCR with fluorescent Taqman
probes is a quantitation detection system utilizing the 5'
3' nuclease activity of Taq DNA polymerase. The method uses
an internal fluorescent oligonucleotide probe (Taqman) labeled
with a 5' reporter dye and a downstream, 3' quencher dye.
During PCR, the 5'-3' nuclease activity of Taq DNA polymerase
releases the reporter, whose fluorescence can then be detected
by the laser detector of the Model 7700 Sequence Detection
System (PE Applied Biosystems, Foster City, CA, USA).
Amplification of an endogenous control is used to
standardize the amount of sample RNA added to the reaction and
normalize for Reverse Transcriptase (RT) efficiency. Either
cyclophilin, glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
or 18S ribosomal RNA (rRNA) is used as this endogenous
control. To calculate relative quantitation between all the
samples studied, the target RNA levels for one sample were
used as the basis for comparative results (calibrator).
Quantitation relative to the "calibrator" can be obtained
using the standard curve method or the comparative method
(User Bulletin #2: ABI PRISM 7700 Sequence Detection System).
The tissue distribution and the level of the target gene
for every example in normal and cancer tissue were evaluated.
Total RNA was extracted from normal tissues, cancer tissues,
and from cancers and the corresponding matched adjacent
tissues. Subsequently, first strand cDNA was prepared with
reverse transcriptase and the polymerase chain reaction was
done using primers and Taqman probe specific to each target
gene. The results are analyzed using the ABI PRISM 7700
CA 02341142 2001-03-O1
WO 00/12758 PCT/US99/19655
- 18 -
Sequence Detector. The absolute numbers are relative levels
of expression of the target gene in a particular tissue
compared to the calibrator tissue.
Measurement of Ovr110; Clone ID16656542; Gene ID 234617 (SEQ
ID NO:l, 10, 11, 12 or 13)
The absolute numbers depicted in Table 2 are relative
levels of expression of Ovr110 (SEQ ID N0:1 or a fragment
thereof as depicted in SEQ ID N0:10, 11, 12, or 13) in 12
normal different tissues. All the values are compared to
normal stomach (calibrator). These RNA samples are
commercially available pools, originated by pooling samples
of a particular tissue from different individuals.
Table 2: Relative Levels of Ovr110 Expression a.n Pooled
Samples
Tissue . NORMAL
colon 0.00
endometrium 8.82
kidney 7.19
liver 0.36
_
ovary 1.19-
pancreas 21.41
prostate 2.79
small intestine 0.03
spleen 0.00
OOOOOOOOOOOOOOstoma 1.00
testis 8.72
uterus 0.93
The relative levels of expression in Table 2 show that
Ovr110 is expressed at comparable levels in most of the normal
tissues analyzed. Pancreas, with a relative expression level
of 21.41, endometrium (8.82), testis (8.72), and kidney (7.19)
are the only tissues expressing high levels of Ovr110 mRNA.
The absolute numbers in Table 2 were obtained analyzing
pools of samples of a particular tissue from different
individuals. They can not be compared to the absolute numbers
originated from RNA obtained from tissue samples of a single
individual in Table 3.
CA 02341142 2001-03-O1
WO 00/12758 PCT/US99/19655
- 19 -
The absolute numbers depicted in Table 3 are relative
levels of expression of Ovr110 in 73 pairs of matching
samples. All the values are compared to normal stomach
(calibrator). A matching pair is formed by mRNA from the
cancer sample for a particular tissue and mRNA from the normal
adjacent sample for that same tissue from the same individual.
In addition, 15 unmatched cancer samples (from ovary and
mammary gland) and 14 unmatched normal samples (from ovary and
mammary gland) were also tested.
Table 3: Relative Levels of Ovr110 Expression in Individual
Samples
Sample ID Tissue Cancer Matching Normal
Normal
Adjacent
Ovr103X Ovary 1 86.22 0.53
Ovr10400 Ovary 2 168.31
Ovr1157 Ovary 3 528.22
Ovr63A Ovary 4 1.71
Ovr7730 Ovary 5 464.65
Ovr10050 Ovary 6 18.32
Ovr1028 Ovary 7 7.78
Ovr1118 Ovary 8 0.00
Ovr130X Ovary 9 149.09
Ovr638A Ovary 10 3.14
OvrAlB Ovary 11 21.26
OvrAlC Ovary 12 1.83
OvrC360 Ovary 13 0.52
Ovrl8GA Ovary 14 1.07
Ovr20GA Ovary 15 1.88
Ovr25GA Ovary 16 2.52
Ovr206I Ovary 1'7 2.51
Ovr32RA Ovary 18 3.01
CA 02341142 2001-03-O1
WO 00/12758 PCT/US99/19655
- 20 -
Ovr35GA Ovary 19 5.17
Ovr40G Ovary 20 0.95
Ovr50GB Ovary 21 2.69
OvrC087 Ovary 22 0.47
OvrCl79 Ovary 23 1.46
OvrC004 Ovary 29 4.99
OvrC007 Ovary 25 13.36
OvrC109 Ovary 26 6.61
MamS516 Mammary 16.39 13.74
Gland 1
MamS621 Mammary 826.70 9.60
Gland 2
MamS859 Mammary 34.60 18.30
Gland 3
Mam59X Mammary 721.57 27.00
Gland 4
MamS079 Mammary 80.73 5.10
Gland 5
MamS967 Mammary 6746.90 72.80
Gland 6
MamS127 Mammary 7.00 ?0.00
Gland 7
MamBOllX Mammary 1092.00 <?9.00
Gland 8
Maml2B Mammary 1392.00
Gland 9
Mam82XI Mammary 507.00
Gland 10
MamS123 Mammary 24.85 4.24
Gland 11
MamS699 Mammary 84.74 5.54
Gland 12
MamS997 Mammary 482.71 11.84
Gland 13
Mam162X Mammary 15.73 10.59
Gland 14
CA 02341142 2001-03-O1
WO 00/12758 PCT/US99/19655
- 21 -
MamA06X Mammary 1418.35 8.20
Gland 15
Mam603X Mammary 294.00
Gland 16
Mam699F Mammary 567.40 86.60
Gland 17
Maml2X Mammary 425.00 31.00
Gland 18
MamA04 Mammary 2.00
Gland 19
Mam42DN Mammary 46.05 31.02
Gland 20
Utr23XU Uterus 1 600.49 27.95
Utr85XU Uterus 2 73.52 18.83
Utr135X0 Uterus 3 178.00 274.00
Utr141X0 Uterus 4 289.00 26.00
CvxNKS54 Cervix 1 2.47 0.61
CvxKS83 Cervix 2 1.00 2.00
CvxNKSl8 Cervix 3 1.00 0.00
CvxNK23 Cervix 4 5.84 14.47
CvxNK24 Cervix 5 20.32 33.13
End68X Endometrium 167.73 544.96
1
End8963 Endometrium 340.14 20.89
2
EndBXA Endometrium 1.68 224.41
3
End65RA Endometrium 303.00 5.00
4
End8911 Endometrium 1038.00 74.00
5
End3AX Endometrium 6.59 1.69
6
End4XA Endometrium 0.43 15.45
7
CA 02341142 2001-03-O1
WO 00/12758 PCT/US99/19655
- 22 -
EndSXA Endometrium 17.81 388.02
8
End10479 Endometrium 1251.60 31.10
9
Endl2XA Endometrium 312.80 33.80
10
Kid107XD Kidney 1 2.68 29.65
Kid109XD Kidney 2 81.01 228.33
KidlOXD Kidney 3 0.00 15.30
Kid6XD Kidney 4 18.32 9.06
KidllXD Kidney 5 1.38 20.75
KidSXD Kidney 6 30.27 0.19
LivlSXA Liver 1 0.00 0.45
Liv42X Liver 2 0.81 0.40
Liv94XA Liver 3 12.00 2.16
Lng LC71 Lung 1 5.45 3.31
LngAC39 Lung 2 1.11 0.00
LngBR94 Lung 3 4.50 0.00
LngSQ45 Lung 4 15.03 0.76
LngC20X Lung 5 0.00 1.65
LngSQ56 Lung 6 91.77 8.03
ClnAS89 Colon 1 0.79 7.65
ClnC9XR Colon 2 0.03 0.00
ClnRC67 Colon 3 0.00 0.00
ClnSG36 Colon 4 0.81 0.35
ClnTX89 Colon 5 0.00 0.00
ClnSG45 Colon 6 0.00 0.06
ClnTX01 Colon 7 0.00 0.00
Pan77X Pancreas 1 0.89 2.62
Pan7lXL Pancreas 2 3.99 0.12
Pan82XP Pancreas 3 59.92 28.44
Pan92X Pancreas 4 17.21 0.00
CA 02341142 2001-03-O1
WO 00/12758 PCT/US99/19655
- 23 -
StoAC93 Stomach 1 7.54 6.43
StoAC99 Stomach 2 19.49 3.19
StoAC44 Stomach 3 3.62 0.37
SmI2IXA Small 0.00 0.00
Intestine 1
SmIH89 Small 0.00 0.00
Intestine 2
B1d32XK Bladder 1 0.00 0.21
B1d46XK Bladder 2 0.36 0.32
BldTRl7 Bladder 3 0.28 0.00
Tst39X Testis 11.24 2.24
Pro84XB Prostate 1 2.60 24.30
Pro90XB Prostate 2 1.40 2.00
0.00= Negative
Table 2 and Table 3 represent a combined total of 187
samples in 16 different tissue types. In the analysis of
matching samples, the higher levels of expression were in
mammary gland, uterus, endometrium and ovary, showing a high
degree of tissue specificity for the gynecologic tissues. Of
all the samples different than those mentioned before
analyzed, only a few samples (Kid109XD, LngSQ56, and Pan82XP)
showed high levels of expression of Ovr110.
Furthermore, the level of mRNA expression was compared
in cancer samples and the isogenic normal adjacent tissue from
the same individual. This comparison provides an indication
of specificity for the cancer stage (e.g. higher levels of
mRNA expression in the cancer sample compared to the normal
adjacent). Table 3 shows overexpression of Ovr110 in 15 of
16 mammary gland cancer tissues compared with their respective
normal adjacent (mammary gland samples MamS516, MamS621,
MamS854, Mam59X, MamS079, MamS967, MamBOllX, MamS123, MamS699,
MamS997, Mam162X, MamA06X, Mam699F, Maml2X, and Mam42DN).
CA 02341142 2001-03-O1
WO 00/12758 PCT/US99/19655
- 24 -
There was overexpression in the cancer tissue for 940 of the
mammary gland matching samples tested.
For uterus, Ovr110 is overexpressed in 3 of 4 matching
samples (uterus samples Utr23XU, Utr85XU, and Utr141X0). There
was overexpression in the cancer tissue for 75% of the uterus
matching samples analyzed.
For endometrium, Ovr110 is overexpressed in 6 of 10
matching samples (endometrium samples End8963, End65RA,
End8911, End3AX, End10479., and Endl2XA). There was
overexpression in the cancer tissue for 600 of the endometrium
matching samples.
For ovary, Ovr110 shows overexpression in 1 of 1
matching sample. For the unmatched ovarian samples, 8 of 12
cancer samples show expression values of Ovr110 higher than
the median (2.52) for the normal unmatched ovarian samples.
There was overexpression in the cancer tissue for 670 of the
unmatched ovarian samples.
Altogether, the level of tissue specificity, plus the
mRNA overexpression in most of the matching samples tested are
indicative of Ovr110 (including SEQ ID N0:1, 10, 11, 12 or 13)
being a diagnostic marker for gynecologic cancers,
specifically, mammary gland or breast, uterine, ovarian and
endometrial cancer.
Measurement of Ovr114; Clone ID1649377~ Gene ID 481154 (SEQ
ID N0:3)
The numbers depicted in Table 4 are relative levels of
expression in 12 normal tissues of Ovr114 compared to pancreas
(calibrator). These RNA samples were obtained commercially
and were generated by pooling samples from a particular tissue
from different individuals.
CA 02341142 2001-03-O1
WO 00/22758 ~ PCT/US99/19b55
- 25 -
Table 4: Relative bevels of Ovr114 Expression in Pooled
Samples
Tissue Normal
Colon 2.3
Endometrium 7.6
Kidne 0.5
Liver 0.6
Ovar 5.2
Pancreas 1.0
Prostate 2.1
Small Intestine 1.3
S leen 2.4
Stomach 1.5
Testis 15.8
Uterus 8,8
The relative levels of expression in Table 4 show that
Ovr114 mRNA expression is detected in all the pools of normal
tissues analyzed.
The tissues shown in Table 4 are pooled samples from
different individuals. The tissues shown in Table 5 were
obtained from individuals and are not pooled. Hence the
values for mRNA expression levels shown in Table 4 cannot be
directly compared to the values shown in Table 5.
The numbers depicted in Table 5 are relative levels of
expression of Ovr114 compared to pancreas (calibrator), in 46
pairs of matching samples and 27 unmatched tissue samples.
Each matching pair contains the cancer sample for a particular
tissue and the normal adjacent tissue sample for that same
tissue from the same individual. In cancers (for example,
ovary) where it was not possible to obtain normal adjacent
samples from the same individual, samples from a different
normal individual were analyzed.
CA 02341142 2001-03-O1
WO 00/12758 PCT/US99/19655
- 26 -
ro
'~
o
"
rl r7 v~ N ~0 0
z
N
01 M rl Q1 O
C
~ M v~ ~ o
-n
x
z
~
U
~ G
~
r) V' V~ M r-I
N M r-i
b ~ O tn u)
a)
0
0
~
d' N o r o v~ m r7
(a U O l0 ~ N O r N
o M o r ~
. -i
-~ .
.ri
'd
H
P1
C9
.ri
O O 3
TJ S-i O
3 rd .f~ .-1
rl .-i
M O 1N -rl N N rt1
N
~ ~ ~ ~
f!l fn (n fn -7-7 O (n tl7 I!) U7
+~ O
N G ~ G ~ ~ G .1-~G G G O
G G . G
o o o s~ s~ ~ m o o o G
b ro ro a7 >, a7 w ro -a
f-1 N S-a O O TJ >r S.a N S-~ -.i
~ E ~ +~ U .y.r~ ~ U
N N UJ ~ ~ r0 U N N U U O
O O O O G O O O S-a
d1 w v7 m :y G +~ C1 ~n tn rf7 S-aG
G G C Ch ra C G c0
-r-t-.--I-,-i+~ .7-~u7 H -,~ -,-i U b -r-i
N G
>, 7r >, .i~ C ?, W >, >, ?n U U
U U U b p U U -.-I
+~
S.~ S-~ N tn u7 U ,-i S-i S~-i S-~ S-~
S-i 1-i l-1 G --i -,-iG 1--if-~ 1-i
~0 rt1 N 'J G ~--IG r0 rt1 rtf G
rti rtJ c0 N .--i c0 ~U rd J-!
N .-I r-I r--IO O p~7 U ,-i ,-i ,-i N U
U U U G S- cp G tJ U N
N rl .-I rI t. G G -r-I.1 .-i .-i -r1O
O O O o ~ ~ O~ O O ~
r-IU -.~ -~ -.i -~~ -~-iO .--~-,..i-.-i -~ 5.~C
G G G -~i "C7 -~ c~ G O
N Q' ~ 0 ~~ ~
C U O ~
r ' t N O ~ O ~ ~0 O D 'tS
0 ' O ~ -tJ -W
'
O U w w w ~ ~ cn c~ w w w O r.
it r~ r~ ~ ,p ,--~~ ~0 r0 o7
4.1
0
0 N Q
p 2 N
r-I M Cn z aW o -
o w n o o~ U U D
.--iH W r.~ o ,-i ,-i
0 q ~ M
O ~ ~ ~ ~ o~ O O O O
r ~ o ~r ~r o M o r u7 00 0
41 m N ,-, oc7 0~ ~ ~ ~ .n o N
0 0 o c, o ~ v~ o .-~ o o v
--p ~ C7 a. r,C .-a ,-m -, r-, ,~ ~ ~--i
1-a S-i S-a y S-a !-~ f-a s-i S-i S-i N S-I
O O O C7 O O O O O O O O
_
0
O rl N
.-~ N f'7 v~ W l0 r 07 01 rl r-ir-i
m
J, ~t ~-, "~ ', ', 'r ~t ~, ?W ,
N S-i 1-i f-i S-i S-~ S-i 1-a S-i S.~ S-W .1 S-a
ro ~ ro m ro b b ro b ro b ro
wI D D ,~ J p ,~ p r~ D b ~J D
H o 0 0 0 0 0 0 0 0 0 0 0
H
~n o
CA 02341142 2001-03-O1
WO 00/12758 PCT/US99/19655
- 27 -
l0r-~ O ~
~ lp r-IO N Q1 ('~1N
O r-i f~ O~
O (p ~ tnN O tn f~'7
N O N N ~
N
'~t' ~ O O
t~ ~ cr v~
v' ~ ao to
U
+~
O ro
ro U ro _
-r-I -~-I ~ i-i O
U S-a .-71-m --i y-~ S-~
.i ro U ro U O
~ ~ ~ -ri
O O O
tn to tn tT .-I -O O
o s~ a~ roa~ o
ro o o o ~..~ r-, ,~,~ w
ro ro ro
S-I h.t S-i U ro p, S-if1
~ ~ ~
T3 4J O O -~-1U -ri f-i-rl rl N b
O O O O U
~.1 (f7 v) tn +.~~ -1-~O .~..W--I CT 1~
~ C C ~ -.I
o -~I -~I -.~ m w .-, E ~ ro s~ cn
-.~ ,-~ ro
-rl ?~ ~ >, >,O ~ N ~
U U U U u1 a
S-i S-~ Sa Sa U ~ ~ .~~ 1 r-I U
S-I s.a !a >.~ >, b~
.1-~ ro ro ro U 1 I I I -,1
rt ro rt1 ro
~ r-I .-i .-~ r-I.-i .-i I-1.-a .-I .-iC r-Icf) rl
U U U U .-I
~ ~ ~ .-~ roro ro roro ro roo~ ro ~ ro
o o o o rl cn u~ ~n ro
o -~ -.~ -~I ~ E ~ ~ ~ ~ ~ -~ E o
t~ ~ ~ ~ .~ a w +~ w ~
v a o~ a. s~a sa ~Isa s~ s~c >.~
a~ o a~ v ro ~ ~ ~n m
ro ro ro 0 0 o o o o o a~ o a~ 0
b -d -0 ~ >, ~, >, >, 0
w w a~ w z z z z z z z m z cn z
ro ro ro ro u~ U U U U c
as
C~ U c7U ~ - ~
~
cx ro
o m o uoo r N o~h av
W -1 N N ~ N M O ~ f''- M
M O O O O O O r-IO r-1 O
U 7C U U U U U U U U U O U
O ~ O N N ~ N N rl f--iN f-I~ .-I
O M 00 O lfl O O O O O O ~ O ~D O
M f~ Oo h O t~ f~h I~ h h v' f~ v~ f
dl '-1 !'~ 01 (TN O1 0161 01 O\ 6101 Ol .-i Ol
.
~-I S-I I~-IS-1 1-1!a S-1 S-I~1 ~1 S-i~iS-1 ~i S1 S-1
D D D ~ D ~ ~ 5 D D ~ ~ D D D
O O O O O o O O O O O O O O O O
M V~ tn lD t~O 01 O r-1 N ('~v'Lfl l0 f1 00
N N N N N N N N N
?, ~, ?n ? W, ~r ','~r ~ ~, ?,~, ~-,?~ 7,
S-i S-i S-i 1-i 1-iS-i S-i i~f-a 1i N S-~S-i S-ila Sa
ro ro ro ro roro ro roro ro ro roro ro ro ro
5 ~ > ~ 5 ~ ~ > >
O O O O O O O O O O O O O O O O
~n o ,r-~
'-., r--,
CA 02341142 2001-03-O1
WO 00/12758 PCT/US99/19655
- 28 -
r ~ ~)O y O V~ IO UW -I O ~ O v~ N
0, v~ m r r M r ~r av o a~ r o~
0 , ,
.-i O~ M O ~ r M O O r-I N ~ tf)r v~
O M N N M ~ 'r o~ ~ N M N
M OO M l0 r-i v' r <r ~ O N
r-1 .-~ ~ M r7 ~r o c~ ~ O O
N
O
N 'LJ
N -1G
U W
U -.-I .-i En
rlN FC ~ ~C - r,~ Z
r-, o a~ z z z N z \
o w w \ \ \ ,..~\ N
U ~ ~ ~ ~ >~
H
r-i -~-1'd O O O O O a
~C
~I +.>Z .-i ~ r-i 'O C +.~
C C G
it W ~ cb rtf b G -~i
\ -.-~-rl -~i E-~
>,I-W -.-i.i -~ N U H
0 U U U ~C
~ G
U N N N N z N
>~ N 1.-iN
I i ~ +~ +~ +~ r-, rt z ro
o ro ro m \
.-i~ .-IrIt0 ~ O N N U \ G
G U U U
rtfrt7 rt1N N ~ ~ ~ ~ O N tn
rn -~-I O O O N
N O O O O~ C O -ri
U G G G U
N N N N -D "O 'b RJ r~
v~ N O N N G
0 0 0 0 o G G G .u -o a ~o
~ ro -o ~ -o ~
z z z z ~ W W W cn r.~E-~
U U rt1 r0 ~0 U
~C ~C ~ o~
N ~ N l0 O Lu ~ O O
r.>r \ \ ~,. z f~ ,-i a~ ~ m o~
r r 01 r y D ~ ~ ~ \ N \ O M tf7e-i
~D r0 r-~ N M v~
O ~ O r rl i.I1~ N O N .---iGW I7 \ r-ir-I
O O r-I~-i~ O N r-i D N \ ~'I cX~ l0 \ \
U U U U M U U r~ N ~ C~, N \ ~ O O
N '-1 ~ r-Il0 Q1 v~ ~ v' I O M ~ O 01 r
O O r-1O O O O O O Ol N O O M ttW-f
r~ r C~ r v' r r r O Q1 ~O O ~ M M v~
01 01 01 Q1,-~ a1 01 01 O U7 r--iv~ ~ N .-Ir-i
N N N N -O '~ 'd 'O ~ ~ ~ ~ N N N N
5 ~ G G C G N ~ ro ro +~ +~ +.>+-~
O O O O W W W W ~ ~ ~ ~ ;~ ~ ~ p
N M cr '~S "d 'b
s~ G G C
E ~ ~ rt m rt ro
a a ~ ,-,
-.-I wi .-I -..~U' C7 C~ C7
01 O rl N N N N N r-i N M cr
N M n7 M ~J .u JJ .1J
N N ~ N S-~ s-~ f..pn cn tf)u7
>, >, ~, >,~ ~ ~ ~ b ro m ro a a a a
N N N N o 0 0 o N N N N
b ro ro ~ ~ ~ b ~ ~ ~ ~ ~ ~ ~ o a~
a ~ ~ C G G G rtt rt1 cD ~0 +~ +~ +.~+i
0 0 0 o w w w w ~.-a~N ~M ~~ ~ a a
~n o ~ o
N
CA 02341142 2001-03-O1
WO 00/12758 PCT/US99/19655
- 29 -
H 01 N M O1 ~ v~ M 01 O IW f1 O N N N 01
M 01 N O 01 M rl 1~ ~-ICO O N f~ O CON M
M ~ v O O O tfW 11 O .-i N O v~ O H '-i
l~ 01 ~ M ~ M H cr ~-iO'11'~ ~ M .-if~~-iN
V~ Ol V~H O l0 cr r-I61 l0 CO (J1O~N N
I,n Q' ~ rlv-I O .-IN .-I~--IO ~ N O O O rl
ri CT O~
.-i G G
N -~i .-1
U N N
-ri -.-i I-i
u1 C C ro U
G
O -V a-.> O G +.i
ro ro -rl d G H H
H
ro ~ ~ ~ ~ ro
~
a~ a~ -~ o a z z
z
tr' x x rn a~ tr \ \
\
cn G ~ c +-~ ~r -a ro ro
ro
'~
o~ o o ~ o ~ r 0 0
o ~ o
G +~ H ~ ~ c G
~ z
.1 ri .-i -rl U E-~ -i H -rl-.-1
FC \
N .-i .-1 .'~, -.-1~ .--IF~ ?~ U U
of ro ro U z ro
a~ ~, .~ z a~ z s~ s~
~ s~ \ ~ ro
C U U ro ro \ U \ ro ro ro
O O O ro ro O ~
-.-iG C H +-~ S-i O S-~T3 U U
C U ~ G O
-N N O .-I v7 N .t-~v G O O
-rl -~-i-rl O -.-I G
ro b~ CT -.-i ro U ro U O G G
U U U .-i U U ro
1-i S-~ ~ GL +~ C C1 G U O N
S-a S.a 1-~ ~-i S-~ S-r H
a~ ro ro ro v ro a~ ro w
ro ro ro a~ ro ro a~
'.~ a a LL ~ U ~ U U7
U U U U c~ U ~
O ~t7a.) N Q~c
M 2 Z D CO ~-I f~ \ W O CO Of7
CO \ \ f~M O \ r-~Q', \ O \ \
\ C7 Ca E '.4 '..v~ U ~ fx M \ ao ~ w r r.~
M M V~ ~'O~ U N H 07 Q1 ~l' ~f7d'
N N N ~ N O r-Iit1 N O 1'~ f~ N I~ O a~ M
0 0 0 ~ M ~ ~. r \ .--~r-, ~ ~ w o ~o
O O O \ \ t~Ll \ ~ U \ O N N x ~ N
O O O E-~x M N U O N I~ O CX.'u7 N v~ N
'-"yC~ D ~ f~ O ~ O O1 O T ~ 01 O O O GO
z Z ~ l0N O N ~ a0 u-tC~ z fn O c0O 01
~r' H H ~9~ V'.-I(~ 00 01 r-I ~ N v~ a1~ V1
M
x x x 'ov -r~v ~ tr~o~ 5 5 G ~ H O O
G G G -.~ -..,x x ~ +~
U U cW n m x x a a a ,a a cn cn cncn ~n
H N J-tH N
~-1 N M r1N C
f-~ ~-n N H .C
x x x w n~ >,>. .-~ N M H N U U
-a-o a~a~ ~ ~ .-~ro ro
> ~ 'oa c G a~ ~r ~r a~ a~ G ~ ~ E
s~ s~ roro 2sz3 G G ~ a ~ -~ ~~ roo 0
a~ a~ a~ .-a~ -.~-.~~ ~ a -~ -~ x .x E
U U U a7f~ x x a a a a a c!W n cOcn U7
O tt7
r-i ~-1
CA 02341142 2001-03-O1
WO 00/12758 PCT/US99/19655
- 30 -
~f7 ri 00N N N N ~O M O r
f'1 l0 M t(7N r ~D N tn'--i r
O N O O rl ri O r-ir-r.--i N
r a~ o o mo ~r oo ~r v~co ~o
C~ M r-1M l0 N ('-1C~ 61M l0
O N O N rt rl O O r-if'~ ~-1
.--i
t0
O
+~
'ri ~ ~ ~ ~ F~
o z z z ~ z
S-t \ \ ~.- U \
+-~ b b ~o ro a~ ro
ro
rn ~ ~ ~ E U
~
ro 0 0 0 0 0 0
o
tr c a ~ ~
~
a~
~ U H 'b En U U O U
-t-~ U
G 1a FC tb ~ Y-a N ~-I S-i
i-a
b ~ z z ra ro o ra
-i ru
~ U \ U ~..U U U U
r0 U
CT O 1,.~-rif-iO O O O
~
-.-iC O 1-~O C C
O
-i N ~ ~ ~ N N U N
1-i N
ro z7 ~ ~. ~ z3 -o ~n -U
+~ ~
~ ~C E- U H r.C ~C r-C ~C
~n rt3
to o~u~ u~
a1 W \ Cp fl7O N
M ~ b \ \ O \
U ~ a W, G1 x a r a~\ rx
\ o o r m o co r.~y o
r-Ir1r N a' ~O N t1~O N
OO \ \ r a0 N O M 01O p
N a.7CG\ \ \ U r to(n U
r N c~p, ~1,x ~o v~ ~rN a
a~ ,~ o o c a~ 0 0 0 .-~ o
0 o r N M r o o ~o r
(n ri r-1r OO N Q1 v v ~01 01
O O O G ~ J--tG C ~ C
1~ S-IS-1f0 Zf UI ri .-ir1r-i r-i
(~
cn w w w w E~ U U U U U
1-~
r-IN rl N
M
N N W ~ .-i
l~ i-~(0 (C1 ~ N f'~~ t1~
U b roa~ a~ cn
~a ~ ~ s~ s-a-~ ~ ~ ~ c c
tO ~nU U +.~O O O O O
O O O ~ ~ m ~ ~ .-i.-i .--i
a--'N s~rt1b N O O O O O
~ E-1U U U U U
O
CA 02341142 2001-03-O1
WO 00/12758 PCT/US99/19655
- 31 -
Table 4 and Table 5 represent a combined total of 129 samples
in 17 human tissue types. Among 117 samples in Table 5
representing 16 different tissues high levels of expression
are seen only in ovarian cancer samples. The median
expression of Ovr114 is 14.03 (range: 0.5 ~- 106.08) in ovarian
cancer and 4.34 (range: 0 - 22.09) in normal ovaries. In
other words, the median expression levels of Ovr114 in cancer
samples is increased 3.5 fold as compared with that of the
normal ovarian samples. Five of 12 ovarian cancers (42%)
showed increased expression relative to normal ovary (with 95%
specificity). The median expression of Ovr114 in other
gynecologic cancers is 4.99, and 2 out of 15 samples showed
expression levels comparable with that in ovarian cancer. The
median of the expression levels of Ovr114 in the rest of the
cancer samples is 1.24, which is more than 11 fold less than
that detected in ovarian cancer samples. No individual showed
an expression level comparable to that of ovarian cancer
samples (except Liver 2; LivVNM00175/175).
The 3.5 fold increase in expression in 42% of the
individual ovarian cancer samples and no compatible expression
in other non-gynecologic cancers is indicative of Ovr114 being
a diagnostic marker for detection of ovarian cancer cells.
It is believed that the Ovr114 marker may also be useful in
detection of additional gynecologic cancers.
Measurement of Ovr115; Clone ID1283171; Gene ID 332459 (SEQ
ID N0:2 or 14)
The numbers depicted in Table 6 are relative levels
of expression Ovr115 compared to their respective calibrators.
The numbers are relative levels of expression in 12 normal
tissues of ovaries compared to Testis (calibrator). These RNA
samples were obtained commercially and were generated by
pooling samples from a particular tissue from different
individuals.
CA 02341142 2001-03-O1
WO 00/I2758 PCT/US99/19655
- 32 -
Table 6: Relative Levels of Ovr115 Expression in Pooled
Samples
Tissue Normal
Colon 858.10
Endometrium 12.34
Kidne 3.76
Liver 0.00
Ovar 0.43
Pancreas 0.00
Prostate 8.91
Small Intestine 62.25
S leen 0.00
Stomach 37.53
Testis 1.00
Uterus 47.67
The relative levels of expression in Table 6 show
that Ovr115 mRNA expression is detected in all the 12 normal
tissue pools analyzed.
The tissues shown in Table 6 are pooled samples from
different individuals. The tissues shown in Table 7 were
obtained from individuals and are not pooled. Hence the
values for mRNA expression levels shown in Table 6 cannot be
directly compared to the values shown in Table 7.
The numbers depicted in Table 7 are relative levels
of expression of Ovr115 compared to testis (calibrator), in
46 pairs of matching samples and 27 unmatched tissue samples.
Each matching pair contains the cancer sample for a particular
tissue and the normal adjacent tissue sample for that same
tissue from the same individual. In cancers (for example,
ovary) where it was not possible to obtain normal adjacent
samples from the same individual, samples from a different
normal individual were analyzed.
CA 02341142 2001-03-O1
WO 00/12758 PCT/US99/19655
- 33 -
ro
a
'~
o
"
U N rn v
ro
~ _ o
0 0 0
U
G
h N
r v M t~ r
.rl
r~ ,-.a ~ ?
N N . cry c
,"
~
b ~ V rl Q1
N
LI rl M N H
r~
~t
~ ~--IQ tn
N N Q'~ c O f~
N
G,' lh H c t~ O v
ro 01 O (''l C O t1~ ~ t0
U ~"~ N ~ ,-i rW
'd
H
i
U
N O 3
y
r 3 17
a r-1
M 1~ O -~ rtf N
rp
~ ~ ~ O U
~
N rn m cn ~n v~ m cn v~
~
,. C C
o o o a s~ a~ m o ro o o o
~o ro ro m >, v b ro ro b
1.-i~~~ N~ ON O+~ T3U ~~~ 1-1~~ S-i~N~
N N N ~ ~ rt1 U ~ -D ~ N N
Q O O O G O C O O O O O O
, N cn ~n m a ~ +~ f~.,cn -.-~cn m m
G c C -..~a, ro ~ C ~ G C
x -~ .~ .~ ~ .u m s-~
.--~ ~
~ ~ ?i ?, S-~ .~- yr b ?, .~-1~ ~, ?i
U U U b~ +.~ U U U U U
S-i S.a S-a o1 ~ U .--iS-i W-I 1.1 S-a l.a
S-i S-a 1H N ~ -rl ~ Y- N S-r ~ ?-i
~ b ~a ~ ~ .-a ~ ro +~ ~n co m
ro ~ ro b ro m ~a ro ro ~a ro
N rl ~ .--tO O u7 U rl N r1 ~ rl
U U U N G N ~ U U U U U
Q1 .-I .-a .-1 C G ~ .-1 .-i ~ -i ~ rl
O O O O 1T ~ tT O O O O O
ri U .rl -.i -.-~-~ -~ O .-i -ri O -..i-.-i .ri
C ~ ~ ,~ -.-i -.1 C ~ G ~ ~
ro ro b ro ~ ~ o ~' ~'' =
d b o '
- - . ro v o ro~ ~-~ r r ro
m av o-o oo
U W w o-~ ~ ~ v7 t~, P.~ W w as w
D rtf N W ~ .-1 ~ rt7 ~0 ro r0 cd
4a
O
UI ~ Z
rl M V7 Z ~D m
N o \ ~ ~ o U U o
1 y -I H \ O F(,' r1 e-i ~p
Gl \ l1 W FC \ ~ ~ M
H O Q' H O M O O ~h O N
Ul M N -i N W l0 lfl v .-.1O M Co
rl O O O O O v q O v M f~ OD
C~ C7 ~C r.~ ri .-i r-i o~ ,-W - p~
3-I S-I ~-1 1..1S-I S-! S-1 S-I S-1 S-I S-1 1-1
O ~ O O O O O O O O p
O O
N
(~'
N M I~ m
M Q' N U1 .-i N ~O N N N N
?r ?W r 7, ~, r'~r', J, ?~ ~, ~, J,
U) ~ S-i N la ?.1 ?.1 S.1 5...~1.-~S.~ y~ y...~
ro ro ro ro ro ro m ro a~ ~o ro m
~ ~ ~ 5
t-~ 0 0 0 0 0 0 0 0 0 0 0 0
H
0
CA 02341142 2001-03-O1
WO 00/12758 PCT/US99/19655
- 34 -
~0 0 0 0 .-, o m o '~ ~ 0 0 0
r-1O O O d1 O N O ~ O O O O
O O O O O O O O ~ O O O O
h
O M h O
N . O
N ~
M ~ O O
h ~r
G ~ ro
ro ro
-~1 a~ o
v s~ a >-t .-I s~
ro U ro U .p
ro -~ > 5 -'-I +~
ro c1 o a~ o .-~ cn w
cn m ~ o cn ~1 >. o
o
O S-a O ro N O U
O O C ro .v-~.-1 ,>~ .-I 4-r v
ro -.~
E 1. .-I
~ O ro ~ ~
U
N N U -~-IU - S-t - r-i ~ ro
O S-~ -.~ U
tn Y-I~ .~.-~-4-~+~ O .i.Wl tT
ro -ri .1.~
-r-IU ro -~-Itn 4-1 .-i ~ .-i ro s-i u1
.1..~ O ro
?~ >, U U J-~O ~ cU ~ C~ ro >,
U -rI v1 -.--I C
1-~ Sa S-aU .-1 ~ .~ ~ u7 ri U
1.~ s-I ~ s-i tT
ro ro ~ ro U 1 I I t 1.~ -.-I
ro 1.~
r-i .--iro U .-I.1 .-i ~-I rl ~-t .-1C r-Icn .-I~-i
U N ~ .-I
-I ~ -.-1O ro ro ro ro ro ro ro tT ro ~ ro ro
O ~ .-I tn u7 u1 c~ ~ b
-.-I-,-IS-iC ~ a~ ~ ~ ~ ~ ~ -,-IE O
G O ~ +-~ .a-i+.~ +~ O ~
a. a. ro a~ s~ ~I sa ~ la ~ ~ s~ s.~~ s.l~.,
a~ ~ ro u~ I cn m -o
m
ro ro ~ '~ O O O O O O O N O a~ O O
T3 C >~ 7, >, 7, ?~ C O
a. w O FC z z z z z z z m z cn z z
ro N u~ v v v v m >~
C~7 c~7 C~~ ~7 ~ ~-x
C c rx ro
O W O tn O h N 01 h 01
r-Ir-1 N N N CO M O tn h M O
O O O O O O f-iO r-1 O O
O O O M U U U U U U U U V O U U
h tn 07 O N .--iN N r-i .-a N rl r-1 ~ .-i r-iN
O N lO O lp O O O O O O r-I O l0 O O
0 o ~r h o h h h h h r, v~ h ~ h h
.~ .-i ,-Iri 01 N 01 01 Q1 01 0161 O~ 01 f-i Ol 01
1-r S.-iS-~F.-~f.!N 1-I ~ S-1 S-~ !aS-aS-~ S-iS-i f-1S-i
~ 5 ~ ~ ~ ~ ~ 5 ~ ~ ~ a
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
O .-aN M ~r m ~ h o~ o ,- m~ u~ a~
f 01 '-i.'-1!-i .-I e-I n-1 r-1 r-1.~ N N N N N
~
7, J, 7, ~ ~ ~ ?i ?n ~ ~, ~ 7, ~, ~, ?o ~ ~r
S-~ Sa Sa ~-iSa t.~ l1 S-i f-a Sa S.rSa Si S~ Sa S-If-I
m ro ro b ro ro ro ro ro ro roro ro m ro ro ro
D D D ~ D D D D P ~ a ~ > 5 D D D
O O O O O O O O O O O O O O O O O
O In
r1 ri
CA 02341142 2001-03-O1
WO 00/12758 PCT/US99/19655
- 35 -
0 0 0 o r o ~ d. o N m ~ .-,
O 0 0 ~ ~ 'nN N ~ N Q r N
M , 0~0 M
O O O M N ~ ~ Q1 O~ N ~ ' ' r
r-I
N M v .-( M r .-iN O Q,v
r N r r N O O
~
M ,~~ r-i O r O
,
r1
O ~ O~ . . O N C l0. ~
~ ~ O
M C ~ m N N c0 N M p1 v
~ N c M l0
N
H U
rI U r.~ .,--i
~ ro ~ z
.- H . H E H ~ W .
-I
~( .~ ~C z a FC FC FC ~ ro
ro
o s~ z \ a~ z z z o ~ z
~
o w -a \ sa ~ \ \ \ ~ rr \
o
w a~ (o o w b (o (a ~ -.~ ro
~
U ~ ~ ~ --I ~ E ~ tn ~-i
.-i
-.tO O ~ 'O O O O O N O
U
--I +-~-b ~ ~ N .-I r-i r-i H
t~ ~ >~
r0 v1 C -.~ 'r N N (b U H -ri
H r0 -rl f-I -.-I~C
?~ N U Ei-1-~-i -.-i-ri ~-i -~-i~C ar U
~C U U U U Z
v1 U z S-ir.~~ v S-~ ~ N +~ z S.-mU
S-a N S-i \
I I .-.\b z m ~. +~ro.~~ro+~b rob \ ro~ m
rl rl N U \ C NN NU ~U NU i~~ S-I 'OO U
(~ (a ro a~ o satr s~ ~ ~ >~ m a~ ~ o
m a~ ~ o o o o >~
~ ~ ~ b ~ ~ ~ o ~ ~ ~ '
m c ~ ~ ~
- ~ ~ G ,
~ r-
o o o +-~ b ~ a~ o ~ ~ ~ a~ (u a~ 'o
a, b c -d v ~o (v v
z z z c~ ~ H ~ E w w w ~ U
U U w ro (o ro m
x
a,
~ ~
~ O N i.t~N l CO \ [Q[Q
0
GON ~(,'\ \ O \ ry' \ M
~ ~
r 01 r .-i N M c Q,' l r ~ .-i OJ 01~r F(,'O
9 -1
OD O r ~ \ .-1r-1.-~ t,(~GO N tt7 00 O N r
O .-1ri W l,0\ \ ~(,'O N '--1r \ .-1rl OJ\
U U U \ o~ O O M U U r.>r\ r~ U N N (Y]
r-I n-ir-1~ ~ CSCr '.O 01 d tn U O N 00 ~ N
O ~-iO O ('7~ ~-1p7 O O O O ~ O 01 O ri
r ~r r m M M v ~ r r r m m .ncn o 0
Q\ 01 01 of N .---~~ ,-W T~ Ov 61 r O 01N v r-1
S-i S-iS-a~-( S-iS-~S-~"O -L3 -t7 'i~ b~ CP CPG C O
a a a +~ +~ +~+-~c ~ G ~ c ~ c x .x
0 0 0 ~ ~ o z w w w w a a a cn cnw
N M C
-ri r1 -.1 -rl
C .-iN .--iN M ~r !-I S-r y~ ya U
M M M (y
~ ~ (U ~ ''~ N M ~ N N
~, ?i J, ~ ~ ~ :y
l-I S-J1-IS-i S~-Il-I>--IO O O O CT U~ ~ C ~ U1
(0 cD rtJO N O N -O 2J T3 'O G C C -.-I -.-(O
a a a +~ +~ 1~~ G c c: c a ~ a -x .x
O O O o O :J0 1 W W W 7 a ,-7v7 u70.,
' ~7
~n a u->
CA 02341142 2001-03-O1
WO 00/12758 PCT/US99/19655
- 36 -
r OJ N
' O N ~ ~
Q M N O 01 O M f~ ' O M (~(~ r M
r r-I O l0 O ~ - r-1 C r-~M
O r N M
N ~ h ~ ~ O O O O W ,-i~ 01 O M WO
r-i N
o mn ~ r-~o r ~ rr o ~r o ~ 0 ~
o ,--~o N r .~ o 0 0 0
, 0 0 0
v~ O ~ O O 07 M ~ Lf) f~
O O ~ O O
N O N O O O N O l0
M l0 M
r-i
O
o
N ~
~C FC FC
~
z
-. z z ~ z z
~
m\ \ \ w \ \
b b ~o ~oC b ro ro
~
E
Z
+~ ~ C C in G C C
C
-r1 I-1 E -.-i-I-IN ~ -rl -.-a
\
>, .-I ~ U U -i-~ E-~'CfE-~U U
U rtf +~
s~ a~ z s~ s~~ G ~C ~ur.C~ s~
s~ ~
b U \ b ~aro z z m ~u
ro o -,-~
U O S-i U U C O \ U \ U U
~
-~ N O O b~ ~ -.-IS-iO O
S-a
f.a
' W 0 U C G -rl O +-iO G G
U +~
O
Q, ~ N v -i tn~ O N
S..t cr1
~
W ~ ~
U
x U ~C FC~ tT U H r~ r.~
U 1
-~
W o1 cr
CO Ca Cu
r o W Oa \ c0
Ir.1M v-I ~ .-1O \ \
E- '.4 \ v~ N \ M \ \ v r.~U f2,Cl~>C N I
o ~r co U N ~o r0 v~ u~ m r~ o~\ rw n o 00
.~ l0 N O r-Ir-1 01 f'~ f~ O v M ~ !~ N C l9 N
\ l0 M ,~ \ \ ~ ~-1 ,~ O lO t1)OJ f'~00N O M
0.7\ \ t-~D Cu N \ O x O~ N N \ \ \ U 1
a' En x M N O M f~ O N v N I~ p y 0 a
01 uW '~ O v N O v~ ~ O O N 01 ., , 01 O O
l0 v~
O l0 N O N ~O O f~ z, CO O 61Q1 f~ N M f~ O
.-ilflM ~r v-1.-i rn r-i ,7 01 cr cnCn I~ ~ N 01 v~
-
O ZJ -a TJ 'O p H O O O C C +~ C G
0. - - ~ ~
~ W CO x x ~ ~ .a ~ ~ cn v cn 0.~0.1H U U
7 S
-i
'z3 T3
C C r-a
b rt1
N .-i .-i ,~ N
r--1N C7 C~ -L~r-iN M
r-iN C U1 U1~
+~ ~-1IN ~, ?, .--iN H .-~.~.C ~ Rf r-i N
~0 N N >, ?~ S-i N U U U N N rn
d Ts a~ a~ ~ ro ~ ~ r-,~ r~ro s~ ~ -~ ~ G
~n -b "O C C N
o b ~r Ts -o ~ ~ ~ > ro o o o ~ c ~ ,
+~ a +~ ro m a~ 0 0
w '~ m x x ~ ~ a
a r-, N a ur cn cn~n w w E. c~ U
o
u~ o ~n o
N
CA 02341142 2001-03-O1
WO 00/12758 PCT/US99/19655
- 37 -
r N r ~ o N
r m o ~ o~ o
t1~M p ~ 01 t1)
Or ~r ~ ~ N I'-
N u1 rl '~ N N
-i .-i r-i
tf7a1 Op
O H
C~ N
l0 O rl r O V
r-iN l0 H
M ~ r-1 M r
O r r
M v~
r '-I N
O
(d
a z ~
U W 3' O~
~
E E i
.-
O O CT N N
O
C ~ r-I -.-I
~
~ -'-I-ri .--I r--I
-r-i -ri ~ C
O U N .-~ .--I
U U -.-I -.-I
cd r0
~ fH -.1 N 1.~ N -t-~
1.a S-~ ~
O r0 C U ~ U t0
r~ c0 O O
U U -~-i1-i S-.a
U U ~ C
O O -!-~N N N 4)
-. .-1
~ b O~ C7~
r-i -aG .~G
U U
U N N S-a S.a
tU r-1 C ~
i-~ f-a
~n -o a~ m o m o
-o a~ ro ro
FC r~ x a c a G
~ U U U
x
CO O N M z z
w o w o~ w w
c4 ~ G7 G~
FC ~ Q' M M C
~ O N OJ N N
O O O O O
U O O O
Q' N ~ O O O
O ri O ~ L] []
o ~o r z z z
H H
c ~ x x x
U U U U U U
H N M
M ~ tn
G G ~ -.1 -ri -ri
O O O ~ ~ p
r-ir-i .-1Y~ la Sa
O O O N N N
U U U U U U
CA 02341142 2001-03-O1
WO 00/12758 PCT/US99/19655
- 38 -
Table 6 and Table 7 represent a combined total of 129 samples
in 17 human tissue types. Comparisons of the level of mRNA
expression in ovarian cancer samples and the normal adjacent
tissue from the same individuals or normal tissues from other
individuals are shown in Table 7. Ovr11.5 was expressed at
higher levels in 9 of 12 cancer tissues (75%), relative to the
maximum level detected in all 21 normal or normal adjacent
ovarian samples. All 4 of 4 (100%) ovarian tumors with
borderline malignancy had elevated Ovr115 expression. The
median expression in ovarian cancers (including the ones with
borderline malignancy) was 212.30 while the median expression
in normal ovaries was 0. When compared with their own normal
adjacent tissue samples, expression levels of Ovr115 were
also elevated in 3 of 3 (100%) lung cancers, 3 of 4 (75%)
uterus cancers and 2 of 4 (50%) endometrial cancers.
The relatively high expression levels of Ovr115 in
ovarian and other selected cancer samples is indicative of
Ovr115 being a diagnostic marker for detection of ovarian,
lung, uterine and endometrial cancer.
A homolog of Ovr115 has also been identified in
public data base; 82597613 as gi~2507612~gb~U75329.1~HSU75329
Human serine protease mRNA, complete CDS. This homolog is
depicted herein as SEQ ID N0:9. It is believed that SEQ ID
N0:9 or the protein encoded thereby (SEQ ID N0:15) may also
be useful as a diagnostic marker for detection of ovarian,
lung, uterine and endometrial cancer in human patients.
CA 02341142 2001-03-O1
WO 00/12758 PCTNS99/19655
SEQUENCE LISTING
<110> Salceda, Susana
Sun, Yongming
Recipon, Herve
Cafferkey, Robert
DIADEXUS LLC
<120> A NOVEL METHOD OF DIAGNOSING, MONITORING, STAGING,
IMAGING AND TREATING VARIOUS CANCERS
<130> DEX-0093
<140>
<141>
<150> 60/098,880
<151> 1998-09-02
<160> 15
<170> PatentIn Ver. 2.0
<210> 1
<211> 2587
<212> DNA
<213> Homo sapiens
<400> 1
ggaaggcagc gggcagctcc actcagccag tacccagata cgctgggaac cttccccagc 60
catggcttcc ctggggcaga tcctcttctg gagcataatt agcatcatca ttattctggc 120
tggagcaatt gcactcatca ttggctttgg tatttcaggg agacactcca tcacagtcac 180
tactgtcgcc tcagctggga acattgggga ggatggaatc ctgagctgca cttttgaacc 240
tgacatcaaa ctttctgata tcgtgatac~a atggctgaag gaaggtgttt taggcttggt 300
ccatgagttc aaagaaggca aagatgagct gtcggagcag gatgaaatgt tcagaggccg 360
gacagcagtg tttgctgatc aagtgatagt tggcaatgcc tctttgcggc tgaaaaacgt 420
gcaactcaca gatgctggca cctacaaatg ttatatcatc acttctaaag gcaaggggaa 480
tgctaacctt gagtataaaa ctggagcctt cagcatgccg gaagtgaatg tggactataa 540
tgccagctca gagaccttgc ggtgtgaggc tccccgatgg ttcccccagc ccacagtggt 600
ctgggcatcc caagttgacc agggagccaa cttctcggaa gtctccaata ccagctttga 660
gctgaactct gagaatgtga ccatgaaggt tgtgtctgtg ctctacaatg ttacgatcaa 720
caacacatac tcctgtatga ttgaaaatga cattgccaaa gcaacagggg atatcaaagt 780
gacagaatcg gagatcaaaa ggcggagtca cctacagctg ctaaactcaa aggcttctct 840
gtgtgtctct tctttctttg ccatcagctg ggcacttctg cctctcagcc cttacctgat 900
gctaaaataa tgtgccttgg ccacaaaaaa gcatgcaaag tcattgttac aacagggatc 960
tacagaacta tttcaccacc agatatgacc tagttttata tttctgggag gaaatgaatt 1020
catatctaga agtctggagt gagcaaacaa gagcaagaaa caaaaagaag ccaaaagcag 1080
aaggctccaa tatgaacaag ataaatct<it cttcaaagac atattagaag ttgggaaaat 1140
1
CA 02341142 2001-03-O1
WO 00/12758 PCT/US99/19655
aattcatgtg aactagacaa gtgtgttaag agtgataagt aaaatgcacg tggagacaag 1200
tgcatcccca gatctcaggg acctccccct gcctgtcacc tggggagtga gaggacagga 1260
tagtgcatgt tctttgtctc tgaattttta gttatatgtg ctgtaatgtt gctctgagga 1320
agcccctgga aagtctatcc caacatatcc acatcttata ttccacaaat taagctgtag 1380
tatgtaccct aagacgctgc taattgactg ccacttcgca actcaggggc ggctgcattt 1440
tagtaatggg tcaaatgatt cactttttat gatgcttcca aaggtgcctt ggcttctctt 1500
cccaactgac aaatgccaaa gttgagaaaa atgatcataa ttttagcata aacagagcag 1560
tcggcgacac cgattttata aataaactga gcaccttctt tttaaacaaa caaatgcggg 1620
tttatttctc agatgatgtt catccgtgaa tggtccaggg aaggaccttt caccttgact 1680
atatggcatt atgtcatcac aagctctgag gcttctcctt tccatcctgc gtggacagct 1740
aagacctcag ttttcaatag catctagagc agtgggactc agctggggtg atttcgcccc 1800
ccatctccgg gggaatgtct gaagacaatt ttggttacct caatgaggga gtggaggagg 1860
atacagtgct actaccaact agtggataaa ggccagggat gctgctcaac ctcctaccat 1920
gtacaggacg tctccccatt acaactaccc aatccgaagt gtcaactgtg tcaggactaa 1980
gaaaccctgg ttttgagtag aaaagggcct ggaaagaggg gagccaacaa atctgtctgc 2040
ttctcacatt agtcattggc aaataagcat tctgtctctt tggctgctgc ctcagcacag 2100
agagccagaa ctctatcggg.caccaggata acatctctca gtgaacagag ttgacaaggc 2160
ctatgggaaa tgcctgatgg gattatcttc agcttgttga gcttctaagt ttctttccct 2220
tcattctacc ctgcaagcca agttctgtaa gagaaatgcc tgagttctag ctcaggtttt 2280
cttactctga atttagatct ccagaccctt cctggccaca attcaaatta aggcaacaaa 2340
catatacctt ccatgaagca cacacagact tttgaaagca aggacaatga ctgcttgaat 2400
tgaggccttg aggaatgaag ctttgaagga aaagaatact ttgtttccag cccccttccc 2460
acactcttca tgtgttaacc actgccttcc tggaccttgg agccacggtg actgtattac 2520
atgttgttat agaaaactga ttttagagtt ctgatcgttc aagagaatga ttaaatatac 2580
atttcct 2587
<210> 2
<211> 2070
<212> DNA
<213> Homo Sapiens
<400> 2
cacagagaga ggcagcagct tgctcagcgg acaaggatgc tgggcgtgag ggaccaaggc 60
ctgccctgca ctcgggcctc ctccagccag tgctgaccag ggacttctga cctgctggcc 120
agccaggacc tgtgtgggga ggccctcctg ctgccttggg gtgacaatct cagctccagg 180
ctacagggag accgggagga tcacagagcc agcatgttac aggatcctga cagtgatcaa 240
cctctgaaca gcctcgatgt caaacccctg cgcaaacccc gtatccccat ggagaccttc 300
agaaaggtgg ggatccccat catcatagca ctactgagcc tggcgagtat catcattgtg 360
gttgtcctca tcaaggtgat tctggataaa tactacttcc tctgcgggca gcctctccac 420
ttcatcccga ggaagcagct gtgtgacgga gagctggact gtcccttggg ggaggacgag 480
gagcactgtg tcaagagctt ccccgaaggg cctgcagtgg cagtccgcct ctccaaggac 540
cgatccacac tgcaggtgct ggactcggcc acagggaact ggttctctgc ctgtttcgac 600
aacttcacag aagctctcgc tgagacagcc tgtaggcaga tgggctacag cagcaaaccc 660
actttcagag ctgtggagat tggcccagac caggatctgg atgttgttga aatcacagaa 720
aacagccagg agcttcgcat gcggaactca agtgggccct gtctctcagg ctccctggtc 780
tccctgcact gtcttgcctg tgggaagagc ctgaagaccc cccgtgtggt gggtggggag 840
gaggcctctg tggattcttg gccttggcag gtcagcatcc agtacgacaa acagcacgtc 900
tgtggaggga gcatcctgga cccccactgg gtcctcacgg gcagcccact gcttcaggaa 960
CA 02341142 2001-03-O1
WO 00/12758 PCT/US99/19655
acataccgat gtgttcaact ggaaggtgcg ggcaggctca gacaaactg g gcagcttccc 1020
atccctggct gtggccaaga tcatcatcat tgaattcaac cccatgtacc ccaaagacaa 1080
tgacatcgcc ctcatgaagc tgcagttccc actcactttc tcaggcacag tcaggcccat 1140
ctgtctgccc ttctttgatg aggagctcac tccagccacc ccactctgga tcattggatg 1200
gggctttacg aagcagaatg gagggaagat gtctgacata ctgctgcagg cgtcagtcca 1260
ggtcattgac agcacacggt gcaatgcaga cgatgcgtac cagggggaa g tcaccgagaa 1320
gatgatgtgt gcaggcatcc cggaaggggg tgtggacacc tgccagggtg acagtggtgg 1380
gcccctgatg taccaatctg accagtggca tgtggtgggc atcgttagct ggggctatgg 1440
ctgcgggggc ccgagcaccc caggagtata caccaaggtc tcagcctatc tcaactggat 1500
ctacaatgtc tggaaggctg agctgtaatg ctgctgcccc tttgcagtg c tgggagccgc 1560
ttccttcctg ccctgcccac ctggggatcc cccaaagtca gacacagagc aagagtcccc 1620
ttgggtacac ccctctgccc acagcctcag catttcttgg agcagcaaag ggcctcaatt 1680
cctataagag accctcgcag cccagaggcg cccagaggaa gtcagcagc c ctagctcggc 1740
cacacttggt gctcccagca tcccagggag agacacagcc cactgaacaa ggtctcaggg 1800
gtattgctaa gccaagaagg aactttccca cactactgaa tggaagcagg ctgtcttgta 1860
aaagcccaga tcactgtggg ctggagagga gaaggaaagg gtctgcgcca gccctgtccg 1920
tcttcaccca tccccaagcc tactagagca agaaaccagt tgtaatataa aatgcactgc 1980
cctactgttg gtatgactac cgttacctac tgttgcattg ttattacagc tatggccact 2040
attattaaag agctgtgtaa catctctggc 2070
<210> 3
<211> 1709
<212> DNA
<213> Homo sapiens
<400> 3
agcagactca caccagaact acattccctg gccccctgcc tgtgtgcttc tggccaggcc 60
ttggttggca agtctgaccc gagaaaagga tctgcagaaa atcagactat gggatcactt 120
tgtttgtgca ttgggaatga cattctttcc caccccagga aaacctttgg gactttcaga 180
gacattgtgg ctagccaacc acatggtcag cctcaaagtt gagaggctca gtaaccctcc 240
tatccctaga gaattccaaa gtgtggatgt aatttaacta gaaagccatt ggtgactatc 300
tgtgatcctc tggaagtatg ctatgttgtg tatatcttgc atccaaagcc agagggaacc 360
acaatgacta gtaaaacggt ggtctcaat g cccacttagc ctctgcctct gaatttgacc 420
atagtggcgt tcagctgata gagcgggaag aagaaatatg cattttttat gaaaaaataa 480
atatccaaga gaagatgaaa ctaaatggag aaattgaaat acatctactg gaagaaaaga 540
tccaattcct gaaaatgaag attgctgaga agcaaagaca aatttgtgtg acccagaaat 600
tactgccagc caagaggtcc ctggatgccg acctagctgt gctccaaatt cagttttcac 660
agtgtacaga cagaattaaa gacctggaga aacagttcgt aaagcctgat ggtgagaata 720
gagctcgctt ccttccaggg aaagatctga ccgaaaaaga aatgatccaa aaattagaca 780
agctggaact acaactggcc aagaaggagg agaagctgct ggagaaggat ttcatctatg 840
agcaggtctc caggctcaca gacaggctct gcagcaaaac tcagggctgc aagcaggaca 900
cactgctctt agccaagaag atgaatggct atcaaagaag gatcaaaaat gcaactgaga 960
aaatgatggc tcttgttgct gagctgtcca tgaaacaagc cctaaccatt gaactccaaa 1020
aggaagtcag ggagaaagaa gacttcatct tcacttgcaa ttccaggata gaaaaaggtc 1080
tgccactcaa taaggaaatt gagaaagaat ggttgaaagt ccttcgagat gaagaaatgc 1140
acgccttggc catcgctgaa aagtctcagg agttcttgga agcagataat cgccagctgc 1200
ccaatggtgt ttacacaact gcagagcagc gtccgaatgc ctacatccca gaagcagatg 1260
ccactcttcc tttgccaaaa ccttatggtg ctttggctcc ttttaaaccc agtgaacctg 1320
3
CA 02341142 2001-03-O1
WO 00/12758 PCT/US99/19655
gagccaatat gaggcacata aggaaacctg ttataaagcc agttgaaatc tgaatatgtg 1380
aacaaatcca ggcctctcaa ggaaaagact tcaaccaggc ttccttgtac ccacaggtga 1940
aaaatgtgag cataatactt ctaatattat tgataagtaa ggtaaccaca attagtcagc 1500
aacagagtac aacagggttt ctatttaccc accaactact ataccttt:ca tgacgttgaa 1560
tgggacatag aactgtccta catttatgtc aaagtatata tttgaatc:gc ttatattttc 1620
tttttcactc tttatattga gtacattcca gaaatttgta gtaggcaagg tgctataaaa 1680
atgcactaaa aataaatctg ttctcaatg 1709
<210> 4
<211> 257
<212> DNA
<213> Homo Sapiens
<400> 4
ttaatgggta agtatttttt atatgcttta gctatagcta aagaaaactg atacttaaca 60
aagttgaata gtattattca ctggtgctcc taaaatattg tttttcagtg taaaatatgc 120
atatcttcta tatttaatat gaaagtcttg aaatgtatca gacagaaggg gatttcagtt 180
tgcaaataat gagcaatgta gcaattttaa cacatttcat aaatatatat tttgtcattg 240
gtggagagca ccatttg 257
<210> 5
<211> 359
<212> DNA
<213> Homo Sapiens
<400> 5
gcctgagagc acttagcgtt catgagtgtc cccaccatgg cctggatgat gcttctcctc 60
ggactccttg cttatggatc aggtcaggga gtggattctc agactgtggt gacccaagag 120
ccatcgttat cagtgtcccc tggagggaca gtcacactca cttgtggctt ggcctctgac 180
tcagtctcta ctaatttctt ccccacctgg taccagcaga ccccaggcca ggctccacgc 290
acgctcatct acagcacaag cactcgctct tctggggtcc ctgatcgttt ctctggctcc 300
atccttggga acaaagctgc cctcaccatt acgggggccc aggcagatga tgaatctga 359
<210>6
<211>1372
<212>DNA
<213>Homo Sapiens
<220>
<221> unsure
<222> (6)
<220>
<221> unsure
<222> (9)
<400> 6
ccttanagnc ttggttgcca aacagaatgc ccatatccgt cttacttgtg aggaagcttg 60
9
CA 02341142 2001-03-O1
WO 00/12758 PCT/US99/19655
ccttgggcgc cctctgctgg ccctcctgaa gctaacaggg gcgagtgctc ggtggtttac 120
aaattgcctc catgcagact atgaaactgt tcagcctgct atagttagat ctctggcact 180
ggcccaggag gtcttgcaga tttgcagatc aaggagaacc caggagtttc aaagaagcgg 240
ctagtaaagg tctctgagat ccttgcacta gctacatcct cagggtagga ggaagatggc 300
ttccagaagc atgcggctgc tcctattgct gagctgcctg gccaaaacag gagtcctggg 360
tgatatcatc atgagaccca gctgtgctcc tgggatggtt ttaccaca ag tccaattgct 420
atggttactt caggaagctg aggaactggt ctgatgccga gctcgagtgt cagtcttacg 480
gaaacggagc ccacctggca tctatcctga gtttaaagga agccagcacc atagcagagt 540
acataagtgg ctatcagaga agccagccga tatggattgg cctgcacgac ccacagaaga 600
ggcagcagtg gcagtggatt gatggggcca tgtatctgta cagatcctgg tctggcaagt 660
ccatgggtgg gaacaagcac tgtgctgaga tgagctccaa taacaacttt ttaacttgga 720
gcagcaacga atgcaacaag cgccaacact tcctgtgcaa gtaccgacca tagagcaaga 780
atcaagattc tgctaactcc tgcacagccc cgtcctcttc ctttctgcta gcctggctaa 840
atctgctcat tatttcagag gggaaaccta gcaaactaag agtgataagg gccctactac 900
actggctttt ttaggcttag agacagaaac tttagcattg gcccagt<~gt ggcttctagc 960
tctaaatgtt tgccccgcca tccctttcca cagtatcctt cttccctcct cccctgtctc 1020
tggctgtctc gagcagtcta gaagagtgca tctccagcct atgaaacagc tgggtctttg 1080
gccataagaa gtaaagattt gaagacagaa ggaagaaact caggagtaag cttctagccc 1140
ccttcagctt ctacaccctt ctgccctctc tccattgcct gcaccccacc ccagccactc 1200
aactcctgct tgtttttcct ttggccatgg gaaggtttac cagtagaatc cttgctaggt 1260
tgatgtgggc catacattcc tttaataaac cattgtgtac ataagaggtt gctgtgttcc 1320
agttcagtaa atggtgaatg tggaaaagtg aaataagacc aagaaataca as 1372
<210> 7
<211> 291
<212> DNA
<213> Homo Sapiens
<220>
<221> unsure
<222> (277)
<400> 7
agaatggtag tagtaagaag aagaaaaata gaggatctga atgtattttg aaggtagagt 60
ccactggact tagagatgga ttgaatgtgg aagattaagg aaagggagaa atgaaagata 120
gtcttaggtt tcatcttcag atgactgggt gaacagcagt gttctttgct aagatgggga 180
agactaggga aaagagccag ttctgtattg agcatattat atttaagaca atcccatctg 240
ggtccaaaga caatgttgat tttttttctt agatacntgc cctttaga cc t 291
<210> 8
<211> 1275
<212> DNA
<213> Homo Sapiens
<220>
<221> unsure
<222> (410)
CA 02341142 2001-03-O1
WO 00/12758 PCT/US99/19655
<220>
<221> unsure
<222> (728)..(756)
<220>
<221> unsure
<222> (957)
<400> 8
attctagaac atatgtataa gctaaaaaca gtattttact cagatcagta gttatcgtgt 60
ctatcagcta taaaaaaaat caactgccag ccaagaactt taaaacttta agctgtgtat I20
tatagaaccg ttttgtgtag cattggaata ttgtccattt tgtaagtcat tgtgaatgtt 180
cttaattatc agcttgaagg tatttttgta ttaaaagttg acattgaaga acctaagtgg 240
atgatgggat ttggggccag tagtgaaagt atgtttcctc taaaatattt ccctaaacag 300
tggtatacat ggttatttta ttatgagatt tgtatatgtt ctgtgtttct ctgtgaacaa 360
tgtttcagtc tctctgtcac catatgtaag gggaagtcca caaatatagn actacattgc 420
acaaaactaa aattgttaat tacaagaaaa tataggtgct taccttttga aggtttatta 480
atacatatgg ttgtcacaat acgtatatat gataaatggt gtacatatac agatgtttat 540
ggtgtataaa tttttctata cccaattaga attatcttcc tgattcttt:a ttcaataaca 600
tgctaattcc tcttctatgt tctatagtga cagaatgcta acttttctta taccctggca 660
gaggacagag gagtctggtc taggatgggg aactgaattt ttgaacgaaa aggaaagaga 720
aaggatgnnn nnnnnnnnnn nnnnnnnnnn nnnnnntaat gtttcttagt cattttgatt 7B0
ggccatttga acagtctaca agtttaacgt tatttccagt gaagtaggat ggctgaccta 840
gcaatacatg tttcttcaaa agggtaaaca tgctttagtg acctaaagct aaattttgta 900
catttgacat caggggtgtt ataagtactg cacttaatac aaagctattt ctcaatngtg 960
ttatttttga gacaaatttt tcttcaccat taacttcttg ttggtagctt tttgttttgt 1020
aaaaattgag agatggcaat gcttatctca accagattat ccatctgcag aattaaggta 1080
tgcaactggt aaataaaaga caaatgctcc agtttgtctt tctcaacctt tgagttctta 1140
acctttgagt taaaacctag tctaaatagt gggaatgtct tggtttacag taaggttttc 1200
ttgggaagga tcttggtttt gtgatctatt tgtgaattaa ggagtagatg ttaaccatta 1260
ttttatagat aagtg 1275
<210> 9
<211> 2479
<212> DNA
<213> Homo sapiens
<400> 9
gtcatattga acattccaga tacctatcat tactcgatgc tgttgataac agcaagatgg 60
ctttgaactc agggtcacca ccagctattg gaccttacta tgaaaaccat ggataccaac 120
cggaaaaccc ctatcccgca cagcccactg tggtccccac tgtctacgag gtgcatccgg 180
ctcagtacta cccgtccccc gtgccccagt acgccccgag ggtcctgacg caggcttcca 240
accccgtcgt ctgcacgcag cccaaatccc catccgggac agtgtgcacc tcaaagacta 300
agaaagcact gtgcatcacc ttgaccctgg ggaccttcct cgtgggagct gcgctggccg 360
ctggcctact ctggaagttc atgggcagca agtgctccaa ctctgggata gagtgcgact 420
cctcaggtac ctgcatcaac ccctctaact ggtgtgatgg cgtgtcacac tgccccggcg 480
gggaggacga gaatcggtgt gttcgcctct acggaccaaa cttcatcctt cagatgtact 540
catctcagag gaagtcctgg caccctgtgt gccaagacga ctggaacgag aactacgggc 600
6
CA 02341142 2001-03-O1
WO 00/12758 PCT/US99/19655
gggcggcctg cagggacatg ggctataaga ataattttta ctctagccaa ggaatagtgg 660
atgacagcgg atccaccagc tttatgaaac tgaacacaag tgccggcaat gtcgatatct 720
ataaaaaact gtaccacagt gatgcctgtt cttcaaaagc agtggtttct ttacgctgtt 780
tagcctgcgg ggtcaacttg aactcaagcc gccagagcag gatcgtgggc ggtgagagcg 840
cgctcccggg ggcctggccc tggcaggtca gcctgcacgt ccagaacgtc cacgtgtgcg 900
gaggctccat catcaccccc gagtggatc:g tgacagccgc ccactgcgtg gaaaaacctc 960
ttaacaatcc atggcattgg acggcatttg cggggatttt gagacaatct ttcatgttct 1020
atggagccgg ataccaagta caaaaagtga tttctcatcc aaattatgac tccaagacca 1080
agaacaatga cattgcgctg atgaagctgc agaagcctct gactttcaac gacctagtga 1140
aaccagtgtg tctgcccaac ccaggcatga tgctgcagcc agaacagctc tgctggattt 1200
ccgggtgggg ggccaccgag gagaaaggga agacctcaga agtgctgaac gctgccaagg 1260
tgcttctcat tgagacacag agatgcaac:a gcagatatgt ctatgacaac ctgatcacac 1320
cagccatgat ctgtgccggc ttcctgcagg ggaacgtcga ttcttgccag ggtgacagtg 1380
gagggcctct ggtcacttcg aacaacaata tctggtggct gataggggat acaagctggg 1440
gttctggctg tgccaaagct tacagaccag gagtgtacgg gaatgtgatg gtattcacgg 1500
actggattta tcgacaaatg aaggcaaacg gctaatccac atggtcttcg tccttgacgt 1560
cgttttacaa gaaaacaatg gggctggttt tgcttccccg tgcatgattt actcttagag 1620
atgattcaga ggtcacttca tttttattaa acagtgaact tgtctggctt tggcactctc 1680
tgccatactg tgcaggctgc agtggctcc:c ctgcccagcc tgctctccct aaccccttgt 1740
ccgcaagggg tgatggccgg ctggttgtgg gcactggcgg tcaattgtgg aaggaagagg 1800
gttggaggct gcccccattg agatcttcct gctgagtcct ttccaggggc caattttgga 1860
tgagcatgga gctgtcactt ctcagctgct ggatgacttg agatgaaaaa ggagagacat 1920
ggaaagggag acagccaggt ggcacctgc:a gcggctgccc tctggggcca cttggtagtg 1980
tccccagcct acttcacaag gggattttgc tgatgggttc ttagagcctt agcagccctg 2040
gatggtggcc agaaataaag ggaccagccc ttcatgggtg gtgacgtggt agtcacttgt 2100
aaggggaaca gaaacatttt tgttcttatg gggtgagaat atagacagtg cccttggtgc 2160
gagggaagca attgaaaagg aacttgccct gagcactcct ggtgcaggt c tccacctgca 2220
cattgggtgg ggctcctggg agggagactc agccttcctc ctcatcctcc ctgaccctgc 2280
tcctagcacc ctggagagtg aatgcccctt ggtccctggc agggcgccaa gtttggcacc 2340
atgtcggcct cttcaggcct gatagtcatt ggaaattgag gtccatgggg gaaatcaagg 2400
atgctcagtt taaggtacac tgtttccatg ttatgtttct acacattgat ggtggtgacc 2460
ctgagttcaa agccatctt 2479
<210> 10
<211> 576
<212> DNA
<213> Homo sapiens
<400> 10
ttcaaagaca tattagaagt tgggaaaata attcatgtga actagacaag tgtgttaaga 60
gtgataagta aaatgcacgt ggagacaagt gcatccccag atctcaggga cctccccctg 120
cctgtcacct ggggagtgag aggacaggat agtgcatgtt ctttgtctct gaatttttag 180
ttatatgtgc tgtaatgttg ctctgaggaa gcccctggaa agtctatccc aacatatcca 240
catcttatat tccacaaatt aagctgtagt atgtacccta agacgctgct aattgactgc 300
cacttcgcaa ctcaggggcg gctgcattt:t agtaatgggt caaatgattc actttttatg 360
atgcttccaa aggtgccttg gcttctcttc ccaactgaca aatgccaaag ttgagaaaaa 920
tgatcataat tttagcataa acagagcagt cggcgacacc gattttataa ataaactgag 480
caccttcttt ttaaacaaac aaatgcgggt ttatttctca gatgatgttc atccgtgaat 540
CA 02341142 2001-03-O1
WO 00/12758 PCT/US99/19655
ggtccaggga aggacctttc accttgacta tatggc 576
<210> 11
<211> 890
<212> DNA
<213> Homo Sapiens
<400> 11
caagctctga ggcttctcct ttccatcctg cgtggacagc taagacctca gttttcaata 60
gcatctagag cagtgggact cagctggggt gatttcgccc cccatctccg ggggaatgtc 120
tgaagacaat tttggttacc tcaatgaggg agtggaggag gatacagtgc tactaccaac 180
tagtggataa aggccaggga tgctgctcaa cctcctacca tgtacaggga cgtctcccca 240
ttacaactac ccaatccgaa gtgtcaactg tgtcaggact aagaaaccct ggttttgagt 300
agaaaagggc ctggaaagag gggagccaac aaatctgtct gcttcctca c attagtcatt 360
ggcaaataag cattctgtct ctttggctgc tgcctcagca cagagagcca gaactctatc 420
gggcaccagg ataacatctc tcagtgaaca gagttgacaa ggcctatggg aaatgcctga 980
tgggattatc ttcagcttgt tgagcttcta agtttctttc ccttcattct accctgcaag 590
ccaagttctg taagagaaat gcctgagttc tagctcaggt tttcttactc tgaatttaga 600
tctccagacc cttcctggcc acaattcaaa ttaaggcaac aaacatata c cttccatgaa 660
gcacacacag acttttgaaa gcaaggacaa tgactgcttg aattgaggcc ttgaggaatg 720
aagctttgaa ggaaaagaat actttgtttc cagccccctt cccacactct tcatgtgtta 780
accactgcct tcctggacct tggagccacg gtgactgtat tacatgttgt tatagaaaac 840
tgattttaga gttctgatcg ttcaagagaa tgattaaata tacatttcct 890
<210> 12
<211> 406
<212> DNA
<213> Homo Sapiens
<220>
<221> unsure
<222> (30)
<220>
<221> unsure
<222> (248)
<220>
<221> unsure
<222> (383)
<400> 12
gtgaatgtgg actataatgc cagctcagan accttgcggt gtgaggctcc ccgatggttc 60
ccccagccca cagtggtctg ggcatcccaa gttgaccagg gagccaactt ctcggaagtc 120
tccaatacca gctttgagct gaactctgag aatgtgacca tgaaggttgt gtctgtgctc 180
tacaatgtta cgatcaacaa cacatactcc tgtatgattg aaaatgacat tgccaaagca 240
acaggggnta tcaaagtgac agaatcggag atcaaaaggc ggagtcacct acagctgcta 300
aactcaaagg cttctctgtg tgtctcttct ttctttgcca tcagctgggc acttctgcct 360
8
CA 02341142 2001-03-O1
WO 00/12758 PCT/US99/19655
ctcagccctt acctgatgct aanataatgt gccttggcca caaaaa 406
<210> 13
<211> 462
<212> DNA
<213> Homo sapiens
<400> 13
ggaaggcagc ggcagctcca ctcagccagt acccagatac gctgggaacc ttccccagcc 60
atggcttccc tggggcagat cctcttctgg agcataatta gcatcatcat tattctggct 120
ggagcaattg cactcatcat tggctttggt atttcaggga gacactccat cacagtcact 180
actgtcgcct cagctgggaa cattgggga g gatggaatcc tgagctgcac ttttgaacct 240
gacatcaaac tttctgatat cgtgatacaa tggctgaagg aaggtgtttt aggcttggtc 300
catgagttca aagaaggcaa agatgagctg tcggagcagg atgaaatgtt cagaggccgg 360
acagcagtgt ttgctgatca agtgatagtt ggcaatgcct ctttgcggct gaaaaacgtg 420
caactcacag atgctggcac ctacaaatgt tatatcatca ct 462
<210> 14
<211> 272
<212> DNA
<213> Homo sapiens
<400> 14
gcagcttgct cagcggacaa ggatgctggg cgtgagggac caaggcctgc cctgcactcg 60
ggcctcctcc agccagtgct gaccagggac ttctgacctg ctggccagcc aggacctgtg 120
tggggaggcc ctcctgctgc cttggggtga caatctcagc tccaggctac agggagaccg 180
ggaggatcac agagccagca tggatcctga cagtgatcaa cctctgaaca gcctcgtcaa 240
ggtgattctg gataaatact acttcctctg cg 272
<210> 15
<211> 492
<212> PRT
<213> Homo sapiens
<400> 15
Met Ala Leu Asn Ser Gly Ser Pro Pro Ala Ile Gly Pro Tyr Tyr Glu
1 5 10 15
Asn His Gly Tyr Gln Pro Glu Asn Pro Tyr Pro Ala Gln Pro Thr Val
20 25 30
Val Pro Thr Val Tyr Glu Val His Pro Ala Gln Tyr Tyr Prc Ser Pro
35 90 45
Val Pro Gln Tyr Ala Pro Arg Val Leu Thr Gln Ala Ser Asn Pro Val
50 55 60
Val Cys Thr Gln Pro Lys Ser Pro Ser Gly Thr Val Cys Thr Ser Lys
9
CA 02341142 2001-03-O1
WO 00/i2758 PCT/US99/19655
65 70 75 80
Thr Lys Lys Ala Leu Cys Ile Thr Leu Thr Leu Gly Thr Phe Leu Val
85 90 95
Gly Ala Ala Leu Ala Ala Gly Leu Leu Trp Lys Phe Met Gly Ser Lys
100 105 110
Cys Ser Asn Ser Gly Ile Glu Cys Asp Ser Ser Gly Thr Cys Ile Asn
115 120 125
Pro Ser Asn Trp Cys Asp Gly Val Ser His Cys Pro Gly Gly Glu Asp
130 135 140
Glu Asn Arg Cys Val Arg Leu Tyr Gly Pro Asn Phe Ile Leu Gln Met
145 150 155 160
Tyr Ser Ser Gln Arg Lys Ser Trp His Pro Val Cys Gln Asp Asp Trp
165 170 175
Asn Glu Asn Tyr Gly Arg Ala Ala Cys Arg Asp Met Gly Tyr Lys Asn
180 185 190
Asn Phe Tyr Ser Ser Gln Gly Ile Val Asp Asp Ser Gly Ser Thr Ser
195 200 205
Phe Met Lys Leu Asn Thr Ser Ala Gly Asn Val Asp Ile Tyr Lys Lys
210 215 220
Leu Tyr His Ser Asp Ala Cys Ser Ser Lys Ala Val Val Ser Leu Arg
225 230 235 240
Cys Leu Ala Cys Gly Val Asn Leu Asn Ser Ser Arg Gln Ser Arg Ile
245 250 255
Val Gly Gly Glu Ser Ala Leu Pro Gly Ala Trp Pro Trp Gln Val Ser
260 265 270
Leu His Val Gln Asn Val His Val Cys Gly Gly Ser Ile Ile Thr Pro
275 280 285
Glu Trp Ile Val Thr Ala Ala His Cys Val Glu Lys Pro Leu Asn Asn
290 295 300
Pro Trp His Trp Thr Ala Phe Ala Gly Ile Leu Arg Gln Ser Phe Met
305 310 315 320
Phe Tyr Gly Ala Gly Tyr Gln Val Gln Lys Val Ile Ser His Pro Asn
CA 02341142 2001-03-O1
WO 00/12758 PCT/US99/19655
325 330 335
Tyr Asp Ser Lys Thr Lys Asn Asn Asp Ile Ala Leu Met Lys Leu Gln
340 345 350
Lys Pro Leu Thr Phe Asn Asp Leu Val Lys Pro Val Cys Leu Pro Asn
355 36t) 365
Pro Gly Met Met Leu Gln Pro Glu Gln Leu Cys Trp Ile Ser Gly Trp
370 375 380
Gly Ala Thr Glu Glu Lys Gly Lys Thr Ser Glu Val Leu Asn Ala Ala
385 390 395 400
Lys Val Leu Leu Ile Glu Thr Gln Arg Cys Asn Ser Arg Tyr Val Tyr
405 410 415
Asp Asn Leu Ile Thr Pro Ala Met Ile Cys Ala Gly Phe Leu Gln Gly
420 425 930
Asn Val Asp Ser Cys Gln Gly Asp Ser Gly Gly Pro Leu Val Thr Ser
435 440 445
Asn Asn Asn Ile Trp Trp Leu Ile Gly Asp Thr Ser Trp Gly Ser Gly
450 455 460
Cys Ala Lys Ala Tyr Arg Pro Gly Val Tyr Gly Asn Val Met Val Phe
965 470 475 480
Thr Asp Trp Ile Tyr Arg Gln Met Lys Ala Asn Gly
485 490
11
